

**CHC HEALTHCARE GROUP AND
SUBSIDIARIES**

**CONSOLIDATED FINANCIAL STATEMENTS AND
INDEPENDENT AUDITORS' REPORT**

DECEMBER 31, 2023 AND 2022

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

REPRESENTATION LETTER

The entities that are required to be included in the combined financial statements of CHC Healthcare Group as of and for the year ended December 31, 2023, under the Criteria Governing the Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises are the same as those included in the consolidated financial statements prepared in conformity with the International Financial Reporting Standard 10, "Consolidated Financial Statements." In addition, the information required to be disclosed in the combined financial statements is included in the consolidated financial statements. Consequently, CHC Healthcare Group and Subsidiaries do not prepare a separate set of combined financial statements.

Very truly yours,

CHC HEALTHCARE GROUP

By

Pei-Lin Lee
Chairman

March 13, 2024

INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of CHC Healthcare Group

Opinion

We have audited the accompanying consolidated balance sheets of CHC Healthcare Group and subsidiaries (the “Group”) as at December 31, 2023 and 2022, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2023 and 2022, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2023 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion

thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Group's 2023 consolidated financial statements are stated as follows:

Impairment assessment of goodwill

Description

As of December 31, 2023, the Group generated goodwill of NT\$150,617 thousand and NT\$202,834 thousand as a result of the merger with Shih-Lu Co., Ltd. and with Treasure of Health Co., Ltd., respectively.

After identifying the smallest cash generating unit which can generate independent cash flows, the Group used the recoverable amount of each cash generating unit to assess whether goodwill may be impaired. Since the assumptions used by management to assess whether goodwill is impaired involve subjective judgment and have high uncertainty, we considered the impairment assessment of goodwill as a key audit matter.

Refer to Note 4(20) for the accounting policy on goodwill impairment, Note 5(2) for uncertainty of accounting estimates and assumptions in relation to goodwill impairment and Note 6(13) for related details.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

- A. Obtained an understanding on how management identifies the objective evidence of goodwill impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.
- B. Obtained the report on the valuation of the subsidiary issued by an expert appointed by the management and performed the following:
 - (1) Assessed the expert's independence, objectiveness and competence by reviewing the expert's qualification.
 - (2) Assessed whether the valuation model is reasonable based on our knowledge of the Group's businesses and industry.
 - (3) Confirmed whether the expert uses the same future cash flows relative to the budget for the

future years provided by the management.

- (4) Checked whether the comparable assets adopted in appraisal report are consistent with the actual operations.
- (5) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Impairment assessment of property, plant and equipment

Description

Some of the Group's leasing businesses were not as profitable as expected due to fierce competition in the healthcare industry. The Group assesses the impairment based on the estimated recoverable amounts of leasing assets (shown as property, plant and equipment) where there is an indication that they are impaired. Given that the calculation of recoverable amounts requires significant accounting estimates relying on subjective judgment and uncertainty, we considered the impairment assessment of leasehold assets as a key audit matter.

Refer to Note 4(20) for the accounting policy on asset impairment and Note 5(2) for accounting estimates and assumption uncertainty of asset impairment.

How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

- A. Obtained an understanding on how management identifies the objective evidence of impairment, taking into account certain factors in a consistent manner and ascertained whether the management uses reliable information.
- B. Acquired the asset appraisal report issued by an expert appointed by the management and performed the following:
 - (1) Assessed the independence, objectiveness and competence by reviewing the expert's qualification.
 - (2) Assessed whether the valuation method is widely adopted and appropriate based on our knowledge of the Group's businesses and industry.
 - (3) Confirmed whether the replacement cost, comparative objects and the assets' use indicated on the appraisal report are consistent with the actual operations.

- (4) Assessed whether the significant assumptions applied by the expert are relevant and reasonable and tested the mathematical accuracy.

Other matter – Parent company only financial reports

We have audited and expressed an unqualified opinion on the parent company only financial statements of CHC Healthcare Group as at and for the years ended December 31, 2023 and 2022.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial

statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

- A. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- B. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal controls.
- C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- D. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- E. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- F. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For and on behalf of PricewaterhouseCoopers, Taiwan

March 13, 2024

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Assets		Notes	December 31, 2023		December 31, 2022	
			Amount	%	Amount	%
Current assets						
1100	Cash and cash equivalents	6(1)	\$ 1,891,381	14	\$ 1,472,849	11
1110	Financial assets at fair value through profit or loss - current	6(2)	69,380	1	41,911	-
1136	Current financial assets at amortised cost	6(4)	66,089	1	205,144	2
1140	Contract assets - current	6(23)	68,176	1	61,294	-
1150	Notes receivable, net	6(5)	38,837	-	46,322	-
1170	Accounts receivable, net	6(5)	738,357	5	581,428	5
1180	Accounts receivable due from related parties, net	7	260,123	2	251,851	2
1200	Other receivables		1,093	-	1,925	-
1210	Other receivables due from related parties	7	-	-	71,369	1
1220	Current tax assets		3,416	-	212	-
130X	Inventories	6(6)(9)	605,476	4	527,921	4
1410	Prepayments	6(7)	588,446	4	576,491	5
1470	Other current assets		915	-	12,832	-
11XX	Total current assets		4,331,689	32	3,851,549	30
Non-current assets						
1510	Financial assets at fair value through profit or loss - non-current	6(2)	67,789	1	60,260	-
1517	Financial assets at fair value through other comprehensive income - non-current	6(3)	36,959	-	29,578	-
1535	Non-current financial assets at amortised cost	6(4) and 8	199,745	1	204,337	2
1560	Contract assets - non-current	6(23)	42,933	-	45,457	-
1550	Investments accounted for using equity method	6(8)	9,911	-	8,307	-
1600	Property, plant and equipment	6(9) 7 and 8	5,916,247	43	5,824,668	45
1755	Right-of-use assets	6(10) and 7	110,435	1	104,293	1
1760	Investment property, net	6(12) and 8	1,549,304	11	1,429,043	11
1780	Intangible assets	6(13)(31)	631,150	5	610,157	5
1840	Deferred tax assets	6(29)	93,240	1	88,730	1
1930	Long-term notes and accounts receivable	6(5)	267,299	2	240,563	2
1940	Long-term notes and accounts receivable due from related parties	7	8,174	-	12,049	-
1990	Other non-current assets	6(9)(12)(14) and 8	348,552	3	321,910	3
15XX	Total non-current assets		9,281,738	68	8,979,352	70
1XXX	Total assets		\$ 13,613,427	100	\$ 12,830,901	100

(Continued)

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Liabilities and equity	Notes	December 31, 2023		December 31, 2022	
			Amount	%	Amount	%
	Current liabilities					
2100	Short-term borrowings	6(15)	\$ 359,075	3	\$ 339,545	3
2130	Contract liabilities - current	6(23)	102,379	1	53,726	-
2150	Notes payable		21,216	-	20,993	-
2170	Accounts payable	7	375,894	3	325,733	3
2200	Other payables	6(9)(12)	194,966	1	121,185	1
2230	Current tax liabilities		118,057	1	79,858	1
2250	Provisions for liabilities - current		13,447	-	14,390	-
2280	Lease liabilities - current	7	33,632	-	27,081	-
2320	Long-term liabilities, current portion	6(17) and 8	202,546	1	67,020	-
2399	Other current liabilities		4,793	-	4,501	-
21XX	Total current liabilities		<u>1,426,005</u>	<u>10</u>	<u>1,054,032</u>	<u>8</u>
	Non-current liabilities					
2527	Contract liabilities - non-current	6(23)	657,915	5	645,381	5
2530	Bonds payable	6(16)(20)	1,317,066	10	1,510,024	12
2540	Long-term borrowings	6(17) and 8	3,066,933	23	2,913,273	23
2550	Provisions for liabilities - non-current	6(9)	17,980	-	18,032	-
2570	Deferred tax liabilities	6(29)	99,232	1	91,815	1
2580	Lease liabilities - non-current	7	207,590	1	158,010	1
2600	Other non-current liabilities	6(17)	45,200	-	37,238	-
25XX	Total non-current liabilities		<u>5,411,916</u>	<u>40</u>	<u>5,373,773</u>	<u>42</u>
2XXX	Total liabilities		<u>6,837,921</u>	<u>50</u>	<u>6,427,805</u>	<u>50</u>
	Equity attributable to owners of the parent					
	Share capital	6(16)(19)(20)				
3110	Common stock		1,664,194	12	1,615,531	13
	Capital surplus	6(16)(19)(21)				
3200	Capital surplus		3,716,656	27	3,544,423	27
	Retained earnings	6(22)				
3310	Legal reserve		427,524	3	391,867	3
3320	Special reserve		387,424	3	395,708	3
3350	Unappropriated retained earnings		648,281	5	581,510	5
	Other equity	6(3)				
3400	Other equity		(385,664)	(2)	(387,423)	(3)
31XX	Total equity attributable to owners of the parent		<u>6,458,415</u>	<u>48</u>	<u>6,141,616</u>	<u>48</u>
36XX	Non-controlling interest	4(3)	<u>317,091</u>	<u>2</u>	<u>261,480</u>	<u>2</u>
3XXX	Total equity		<u>6,775,506</u>	<u>50</u>	<u>6,403,096</u>	<u>50</u>
	Significant contingent liabilities and unrecognised contract commitments	9				
3X2X	Total liabilities and equity		<u>\$ 13,613,427</u>	<u>100</u>	<u>\$ 12,830,901</u>	<u>100</u>

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
YEARS ENDED DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS,
EXCEPT FOR EARNINGS PER SHARE AMOUNTS)

	Items	Notes	2023		2022	
			Amount	%	Amount	%
4000	Operating revenue	6(5)(11)(12)(23) and 7	\$ 3,877,137	100	\$ 2,974,352	100
5000	Operating costs	6(6)(9)(10)(12)(18) (19)(28) and 7	(2,808,977)	(72)	(2,072,038)	(70)
5950	Gross profit		<u>1,068,160</u>	<u>28</u>	<u>902,314</u>	<u>30</u>
	Operating expenses	6(9)(10)(12)(13)(18) (19)(28) and 7	(454,684)	(12)	(426,554)	(14)
6100	Selling expenses		(218,424)	(6)	(184,049)	(6)
6200	General and administrative expenses		(235,983)	(6)	(238,348)	(8)
6450	Loss on expected credit impairment		(277)	-	(4,157)	-
6000	Total operating expenses		(454,684)	(12)	(426,554)	(14)
6900	Operating profit		<u>613,476</u>	<u>16</u>	<u>475,760</u>	<u>16</u>
	Non-operating income and expenses					
7100	Interest income	6(4)(10)(11)(24) and 7	20,683	-	12,530	-
7010	Other income	6(11)(12)(17)(25)	7,889	-	13,044	-
7020	Other gains and losses	6(2)(10)(26)	4,779	-	54,102	2
7050	Finance costs	6(27) and 7	(89,001)	(2)	(71,267)	(2)
7060	Share of profit (loss) of associates and joint ventures accounted for using equity method	6(8)	<u>1,604</u>	<u>-</u>	<u>(334)</u>	<u>-</u>
7000	Total non-operating income and expenses		(54,046)	(2)	8,075	-
7900	Profit before income tax		<u>559,430</u>	<u>14</u>	<u>483,835</u>	<u>16</u>
7950	Income tax expense	6(29)	(134,192)	(3)	(95,185)	(3)
8200	Profit for the year		<u>\$ 425,238</u>	<u>11</u>	<u>\$ 388,650</u>	<u>13</u>
	Other comprehensive income					
	Components of other comprehensive income that will not be reclassified to profit or loss					
8316	Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(3)	\$ 7,381	-	(\$ 1,869)	-
	Components of other comprehensive income that will be reclassified to profit or loss					
8361	Financial statements translation differences of foreign operations		(5,682)	-	10,220	-
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	6(29)	(7)	-	(2)	-
8300	Other comprehensive income for the year		<u>\$ 1,692</u>	<u>-</u>	<u>\$ 8,349</u>	<u>-</u>
8500	Total comprehensive income for the year		<u>\$ 426,930</u>	<u>11</u>	<u>\$ 396,999</u>	<u>13</u>
	Profit attributable to:					
8610	Owners of the parent		<u>\$ 418,866</u>	<u>11</u>	<u>\$ 356,571</u>	<u>12</u>
8620	Non-controlling interest		<u>\$ 6,372</u>	<u>-</u>	<u>\$ 32,079</u>	<u>1</u>
	Comprehensive income attributable to:					
8710	Owners of the parent		<u>\$ 420,625</u>	<u>11</u>	<u>\$ 364,855</u>	<u>12</u>
8720	Non-controlling interest		<u>\$ 6,305</u>	<u>-</u>	<u>\$ 32,144</u>	<u>1</u>
	Earnings per share (in dollars)					
9750	Basic earnings per share	6(30)	<u>\$ 2.55</u>		<u>\$ 2.21</u>	
9850	Diluted earnings per share	6(30)	<u>\$ 2.26</u>		<u>\$ 1.98</u>	

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
YEARS ENDED DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		Equity attributable to owners of the parent											
		Capital Reserves				Retained Earnings			Other Equity Interest				
									Financial statements translation differences of foreign operations	Unrealised gains (loss) from financial assets measured at fair value through other comprehensive income		Non-controlling interest	Total equity
Notes		Common stock	Capital surplus	Employee stock warrants	Others	Legal reserve	Special reserve	Unappropriated retained earnings			Total		
<u>2022</u>													
		\$ 1,610,536	\$ 3,462,388	\$ 11,766	\$ 59,145	\$ 353,704	\$ 387,124	\$ 595,565	(\$ 45,539)	(\$ 350,168)	\$ 6,084,521	\$ 229,336	\$ 6,313,857
		-	-	-	-	-	-	356,571	-	-	356,571	32,079	388,650
		-	-	-	-	-	-	-	10,153	(1,869)	8,284	65	8,349
		-	-	-	-	-	-	356,571	10,153	(1,869)	364,855	32,144	396,999
	6(22)												
		-	-	-	-	38,163	-	(38,163)	-	-	-	-	-
		-	-	-	-	-	8,584	(8,584)	-	-	-	-	-
		-	-	-	-	-	-	(323,879)	-	-	(323,879)	-	(323,879)
	6(19)(20)	4,995	14,339	(4,973)	-	-	-	-	-	-	14,361	-	14,361
	6(19)	-	-	595	-	-	-	-	-	-	595	-	595
	6(19)	-	-	1,163	-	-	-	-	-	-	1,163	-	1,163
		\$ 1,615,531	\$ 3,476,727	\$ 8,551	\$ 59,145	\$ 391,867	\$ 395,708	\$ 581,510	(\$ 35,386)	(\$ 352,037)	\$ 6,141,616	\$ 261,480	\$ 6,403,096
<u>2023</u>													
		\$ 1,615,531	\$ 3,476,727	\$ 8,551	\$ 59,145	\$ 391,867	\$ 395,708	\$ 581,510	(\$ 35,386)	(\$ 352,037)	\$ 6,141,616	\$ 261,480	\$ 6,403,096
		-	-	-	-	-	-	418,866	-	-	418,866	6,372	425,238
		-	-	-	-	-	-	-	(5,622)	7,381	1,759	(67)	1,692
		-	-	-	-	-	-	418,866	(5,622)	7,381	420,625	6,305	426,930
	6(22)												
		-	-	-	-	35,657	-	(35,657)	-	-	-	-	-
		-	-	-	-	-	-	(324,722)	-	-	(324,722)	-	(324,722)
		-	-	-	-	-	(8,284)	8,284	-	-	-	-	-
	6(16)(20)	41,933	163,705	-	(3,396)	-	-	-	-	-	202,242	-	202,242
	6(19)(20)	6,730	18,636	(6,998)	-	-	-	-	-	-	18,368	-	18,368
	6(19)	-	-	99	-	-	-	-	-	-	99	-	99
	6(19)	-	-	187	-	-	-	-	-	-	187	-	187
		-	-	(108)	108	-	-	-	-	-	-	-	-
	6(31)	-	-	-	-	-	-	-	-	-	-	49,306	49,306
		\$ 1,664,194	\$ 3,659,068	\$ 1,731	\$ 55,857	\$ 427,524	\$ 387,424	\$ 648,281	(\$ 41,008)	(\$ 344,656)	\$ 6,458,415	\$ 317,091	\$ 6,775,506

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		\$ 559,430	\$ 483,835
Adjustments			
Adjustments to reconcile profit (loss)			
Expected credit loss		277	4,157
Depreciation charge	6(9)(10)(12)(28)	572,563	478,142
Amortisation charge	6(13)(28)	21,900	21,240
Loss on disposal of property, plant and equipment	6(26)	1,331	50,780
Property, plant and equipment transferred to expenses	6(9)	488	1,673
Gain on disposal of investment property	6(26)	-	106,590)
Gain from lease modification	6(26)	(162)	-
Interest expense		104,333	68,538
Interest income	6(24)	(20,683)	(12,530)
Dividend income	6(25)	(1,565)	(3,508)
Government grant income	6(25)	(856)	-
Share of (profit) loss of associates and joint ventures accounted for using equity method	6(8)	(1,604)	334
Net (gain) loss on financial assets or liabilities at fair value through profit or loss	6(2)(26)	(13,089)	17,992
Amortisation of discount on bonds payable	6(27)	9,874	10,646
Compensation cost of employee stock options	6(19)(28)	286	1,758
Changes in operating assets and liabilities			
Changes in operating assets			
Financial assets at fair value through profit or loss		(16,499)	30,701
Contract assets		(4,358)	(2,885)
Notes receivable		4,825	4,747
Accounts receivable		(119,686)	(153,494)
Accounts receivable due from related parties		(2,833)	(11,717)
Other receivables		1,140	4,391
Other receivables due from related parties		369	101
Inventories		(76,688)	(209,228)
Prepayments		(11,955)	(29,191)
Other current assets		11,917	3,147
Changes in operating liabilities			
Contract liabilities		48,653	8,192
Notes payable		223	10,425
Accounts payable		48,702	128,553
Other payables		20,326	7,054
Provisions for liabilities		(2,195)	(2,811)
Other current liabilities		292	860
Cash inflow generated from operations		1,134,756	805,312
Dividends received during the year		1,265	3,508
Interest paid during the year		(86,225)	(53,876)
Interest received during the year		20,683	12,530
Income tax paid		(107,891)	(110,815)
Net cash flows from operating activities		962,588	656,659

(Continued)

CHC HEALTHCARE GROUP AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Notes	2023	2022
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>			
Proceeds from disposal of financial assets at amortised cost		\$ 143,647	\$ 133,099
Decrease in other receivables due from related parties		71,000	91,500
Acquisition of property, plant and equipment	6(9)	(549,672)	(682,633)
Proceeds from disposal of property, plant and equipment		1,068	1,238
Acquisition of investment properties	6(12)	(29,390)	(2,077)
Proceeds from disposal of investment properties		-	166,015
Increase in refundable deposits		(121,739)	(64,515)
Decrease in refundable deposits		67,413	35,078
Increase in other non-current assets		(7,272)	(17,684)
Net cash flows from acquisition of subsidiaries	6(31)	(49,520)	-
Acquisition of intangible assets	6(13)	(26,000)	-
Net cash flows used in investing activities		(500,465)	(339,979)
<u>CASH FLOWS FROM FINANCING ACTIVITIES</u>			
Increase in short-term loans	6(33)	2,104,311	3,481,275
Decrease in short-term loans	6(33)	(2,057,956)	(3,777,941)
Payments of lease liabilities	6(33)	(33,510)	(23,737)
Proceeds from long-term debt	6(33)	515,935	2,635,000
Repayments of long-term debt	6(33)	(271,848)	(2,348,300)
Increase in guarantee deposits received	6(33)	6,874	2,902
Decrease in guarantee deposits received	6(33)	(3,421)	(6,133)
Exercise of employee stock options		18,368	14,361
Payment of cash dividends	6(22)	(324,722)	(323,879)
Change in non-controlling interest		3,921	-
Net cash flows used in financing activities		(42,048)	(346,452)
Effect of changes in foreign currency exchange rates on cash and cash equivalents		(1,543)	8,694
Increase (decrease) in cash and cash equivalents		418,532	(21,078)
Cash and cash equivalents at beginning of year		1,472,849	1,493,927
Cash and cash equivalents at end of year		<u>\$ 1,891,381</u>	<u>\$ 1,472,849</u>

The accompanying notes are an integral part of these consolidated financial statements.

CHC HEALTHCARE GROUP AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2023 AND 2022
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS,
EXCEPT AS OTHERWISE INDICATED)

1. HISTORY AND ORGANISATION

CHC Healthcare Group (CHC or the “Company”) was incorporated in the Republic of China. The shares of the Company were listed on the Taiwan Stock Exchange on October 24, 2012. The Company and its subsidiaries (the “Group”) are primarily engaged in the trading of pharmaceutical products and health food, and the sale, leasing, installation, and repair of medical instruments.

2. THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION

These consolidated financial statements were authorised for issuance by the Board of Directors on March 13, 2024.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS[®]”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2023 are as follows:

<u>New Standards, Interpretations and Amendments</u>	<u>Effective date by International Accounting Standards Board</u>
Amendments to IAS 1, ‘Disclosure of accounting policies’	January 1, 2023
Amendments to IAS 8, ‘Definition of accounting estimates’	January 1, 2023
Amendments to IAS 12, ‘Deferred tax related to assets and liabilities arising from a single transaction’	January 1, 2023
Amendments to IAS 12, ‘International tax reform - pillar two model rules’	May 23, 2023

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC and will become effective from 2024 are as follows:

<u>New Standards, Interpretations and Amendments</u>	<u>Effective date by International Accounting Standards Board</u>
Amendments to IFRS 16, 'Lease liability in a sale and leaseback'	January 1, 2024
Amendments to IAS 1, 'Classification of liabilities as current or non-current'	January 1, 2024
Amendments to IAS 1, 'Non-current liabilities with covenants'	January 1, 2024
Amendments to IAS 7 and IFRS 7, 'Supplier finance arrangements'	January 1, 2024
The above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment.	

(3) Effect of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

<u>New Standards, Interpretations and Amendments</u>	<u>Effective date by International Accounting Standards Board</u>
Amendments to IFRS 10 and IAS 28, 'Sale or contribution of assets between an investor and its associate or joint venture'	To be determined by International Accounting Standards Board
IFRS 17, 'Insurance contracts'	January 1, 2023
Amendments to IFRS 17, 'Insurance contracts'	January 1, 2023
Amendment to IFRS 17, 'Initial application of IFRS 17 and IFRS 9 - comparative information'	January 1, 2023
Amendments to IAS 21, 'Lack of exchangeability'	January 1, 2025
The above standards and interpretations have no significant impact to the Group's financial condition and financial performance based on the Group's assessment.	

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

The consolidated financial statements of the Group have been prepared in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers", International Financial Reporting Standards, International Accounting Standards, IFRIC[®] Interpretations, and SIC[®] Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the "IFRSs").

(2) Basis of preparation

A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:

- (a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
- (b) Financial assets and liabilities at fair value through other comprehensive income.
- B. The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

A. Basis for preparation of consolidated financial statements:

- (a) All subsidiaries are included in the Group's consolidated financial statements. Subsidiaries are all entities controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries.
- (b) Inter-company transactions, balances and unrealised gains or losses on transactions between companies within the Group are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.
- (c) Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.
- (d) Changes in a parent's ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary (transactions with non-controlling interests) are accounted for as equity transactions, i.e. transactions with owners in their capacity as owners. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity.

B. Subsidiaries included in the consolidated financial statements:

Investor	Subsidiary	Main business activities	Ownership (%)		Description
			December 31, 2023	December 31, 2022	
CHC	Chiu Ho Medical System Co., Ltd. (Chiu Ho Medical)	Medical instrument sale, leasing and services	100	100	
CHC	Tomorrow Medical System Co., Ltd. (Tomorrow)	Medical instrument sale, leasing and services	100	100	

Investor	Subsidiary	Main business activities	Ownership (%)		Description
			December 31, 2023	December 31, 2022	
CHC	Chiu Ho Scientific Co., Ltd. (Chiu Ho Scientific)	Ophthalmic equipment sale, leasing and services	100	100	
CHC	Chiu Ho Biotech Co., Ltd. (Chiu Ho Biotech)	Medical instrument leasing	100	100	Note 1
CHC	Shin-Ho Instruments Co., Ltd. (Shin-Ho)	Medical instrument leasing and irradiation business	100	100	
CHC	Tong-Lin Instruments Co., Ltd. (Tong-Lin)	Medical instrument leasing	100	100	
CHC	Hua Lin Instruments Co., Ltd. (Hua Lin)	Medical instrument leasing	100	100	
CHC	Hsin Lin Biotech Co., Ltd. (Hsin Lin)	Medical instrument leasing	-	100	Note 1
CHC	E Century Healthcare Corporation (E Century)	Medical instrument leasing	100	100	
CHC	CHC Healthcare (BVI) Limited (CHC (BVI))	Holdings and indirect investments	100	100	
CHC	Treasure of Health Co., Ltd. (Treasure of Health)	Drug and health supplements sale	51	51	
CHC	CHC Healthcare (UK) Limited (CHC (UK))	Medical instrument sale	100	100	Note 2
Chiu Ho Medical	Hsing-Yeh Biotechnology Co., Ltd. (Hsing-Yeh)	Medical instrument sale and leasing; drug sale	100	100	
Chiu Ho Medical	SenCare Healthcare Company (SenCare)	Consulting service, elderly residence and senior fitness	66	66	
Chiu Ho Medical	PT CHC Medika Indonesia (PT CHC)	Medical instrument leasing	100	100	
SenCare	CHC Long-Term Care Corporation (CHC LTC)	Long-term care services	97	97	
SenCare	Cin-An Co., Ltd. (Cin-An)	Elderly residence	51	-	Note 3

Investor	Subsidiary	Main business activities	Ownership (%)		Description
			December 31, 2023	December 31, 2022	
SenCare	Xing-An Long-term Care Corporation (Xing-An LTC)	Long-term care service	50.7	-	Note 3
Treasure of Health	Exotic Pet Care Experts Co., Ltd. (Exotic Pet Care)	Veterinary medical instrument leasing and drug sale	51	-	Note 4
CHC (BVI)	CHC Healthcare (HK) Limited (CHC (HK))	Medical instrument sale, leasing and services	100	100	
CHC (BVI)	CHC (Guangzhou) Medical Technology Co., Ltd. (CHC Guangzhou)	Medical instrument sale, leasing and services	100	100	
CHC (BVI)	Chiu Ho (CHINA) Medical Technology Co., Ltd. (Chiu Ho (CHINA))	Medical instrument sale, leasing and services	100	100	
CHC (Guangzhou)	Neusoft CHC Medical Service Co., Ltd. (Neusoft CHC)	Medical instrument leasing	51	51	

Note 1: The Company's subsidiary, Hsin Lin, merged with the Company's subsidiary, Chiu Ho Biotech, on December 31, 2023. Chiu Ho Biotech was the surviving company. After the merger, the shareholding ratio of the Company in Chiu Ho Biotech was 100%. The merger has no significant influence on the shareholder's equity of the parent company as it was a reorganisation within the Group.

Note 2: The Company invested and established CHC (UK) on May 17, 2022 and CHC(UK) was included in the consolidated financial statements starting from the establishment date.

Note 3: The Company's indirect subsidiary, SenCare, acquired Cin-An and Xing-An LTC on January 1, 2023 and Cin-An and Xing-An LTC were included in the consolidated financial statements thereafter.

Note 4: The Company's subsidiary, Treasure of Health, invested and established Exotic Pet Care on March 14, 2023 and Exotic Pet Care was included in the consolidated financial statements starting from the starting date.

- C. Subsidiaries not included in the consolidated financial statements: None.
- D. Adjustments for subsidiaries with different balance sheet dates: None.
- E. Significant restrictions: None.

F. Subsidiaries that have non-controlling interests that are material to the Group:

As of December 31, 2023 and 2022, the non-controlling interest amounted to \$317,091 and \$261,480, respectively. The information on non-controlling interest and respective subsidiaries is as follows:

Name of subsidiary	Principal place of business	Non-controlling interest				Description
		December 31, 2023		December 31, 2022		
		Amount	Ownership (%)	Amount	Ownership (%)	
Treasure of Health	Taiwan	\$ 166,085	49%	\$ 158,523	49%	-

Summarised financial information of the subsidiaries:

Balance sheet

	<u>Treasure of Health</u>	
	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Current assets	\$ 406,693	\$ 276,066
Non-current assets	671,001	594,900
Current liabilities	(324,951)	(186,245)
Non-current liabilities	(210,961)	(158,370)
Total net assets	<u>\$ 541,782</u>	<u>\$ 526,351</u>

Statement of comprehensive income

	<u>Treasure of Health</u>	
	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Revenue	\$ 831,734	\$ 826,880
Profit before income tax	19,368	84,113
Income tax expense	(3,936)	(16,856)
Profit for the year	<u>15,432</u>	<u>67,258</u>
Total comprehensive income for the year	<u>\$ 15,432</u>	<u>\$ 67,258</u>
Comprehensive income attributable to non-controlling interest	<u>\$ 7,562</u>	<u>\$ 32,956</u>

Statement of cash flows

	<u>Treasure of Health</u>	
	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Net cash (used in) provided by operating activities	(\$ 47,421)	\$ 45,178
Net cash used in investing activities	(44,546)	(13,253)
Net cash provided by (used in) financing activities	<u>119,855</u>	<u>(2,264)</u>
Increase in cash and cash equivalents	<u>27,888</u>	<u>29,661</u>
Cash and cash equivalents, beginning of year	<u>60,598</u>	<u>30,937</u>
Cash and cash equivalents, end of year	<u>\$ 88,486</u>	<u>\$ 60,598</u>

(4) Foreign currency translation

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in New Taiwan Dollars, which is the Company's functional and the Group's presentation currency.

A. Foreign currency transactions and balances

- (a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognised in profit or loss in the period in which they arise.
- (b) Monetary assets and liabilities denominated in foreign currencies at the period end are re-translated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognised in profit or loss.
- (c) All foreign exchange gains and losses are presented in the statement of comprehensive income within 'other gains or losses'.

B. Translation of foreign operations

The operating results and financial position of all the group entities and associates that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- (a) Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;
- (b) Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and
- (c) All resulting exchange differences are recognised in other comprehensive income.

(5) Classification of current and non-current items

A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:

- (a) Assets arising from operating activities that are expected to be realised, or are intended to be sold or consumed within the normal operating cycle;
- (b) Assets held mainly for trading purposes;
- (c) Assets that are expected to be realised within twelve months from the balance sheet date;
- (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to pay off liabilities more than twelve months after the balance sheet date.

B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:

- (a) Liabilities that are expected to be paid off within the normal operating cycle;
- (b) Liabilities arising mainly from trading activities;
- (c) Liabilities that are to be paid off within twelve months from the balance sheet date;
- (d) Liabilities for which the repayment date cannot be extended unconditionally to more than twelve months after the balance sheet date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

(6) Cash equivalents

Cash equivalents refer to short-term highly liquid investments that are readily convertible to known amount of cash and subject to an insignificant risk of changes in value. Time deposits that meet the definition above and are held for the purpose of meeting short-term cash commitment in operations are classified as cash equivalents.

(7) Financial assets at fair value through profit or loss

- A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortised cost or fair value through other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value and recognises the transaction costs in profit or loss. The Group subsequently measures the financial assets at fair value, and recognises the gain or loss in profit or loss.
- D. The Group recognises the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(8) Financial assets at fair value through other comprehensive income

- A. Financial assets at fair value through other comprehensive income comprise equity securities which are not held for trading, and for which the Group has made an irrevocable election at initial recognition to recognise changes in fair value in other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs. The Group subsequently measures the financial assets at fair value:

The changes in fair value of equity investments that are recognised in other comprehensive income are reclassified to retained earnings. When the equity instruments are derecognised the cumulative gain or loss previously recognised in other comprehensive income is not reclassified from equity to profit or loss. Dividends are recognised as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(9) Financial assets at amortised cost

The Group's time deposits which do not fall under cash equivalents are those with a short maturity period and are measured at initial investment amount as the effect of discounting is immaterial.

(10) Accounts and notes receivable

- A. Accounts and notes receivable entitle the Group a legal right to receive consideration in exchange for transferred goods or rendered services.
- B. The short-term accounts and notes receivable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(11) Impairment of financial assets

For financial assets at amortised cost including accounts receivable or contract assets that have a significant financing component, lease receivables, at each reporting date, the Group recognises the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognises the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable or contract assets that do not contain a significant financing component, the Group recognises the impairment provision for lifetime ECLs.

(12) Derecognition of financial assets

The Group derecognises a financial asset when the contractual rights to receive the cash flows from the financial asset expire.

(13) Leasing arrangements (lessor)-lease receivables / operating leases

- A. Based on the terms of a lease contract, a lease is classified as a finance lease if the lessee assumes substantially all the risks and rewards incidental to ownership of the leased asset.
 - (a) At commencement of the lease term, the lessor should record a finance lease in the balance sheet as 'lease receivables' at an amount equal to the net investment in the lease (including initial direct costs). The difference between gross lease receivable and the present value of the receivable is recognised as 'unearned finance income of finance lease'.
 - (b) The lessor should allocate finance income over the lease term based on a systematic and rational basis reflecting a constant periodic rate of return on the lessor's net investment in the finance lease.
 - (c) Lease payments (excluding costs for services) during the lease term are applied against the gross investment in the lease to reduce both the principal and the unearned finance income.
- B. Lease income from an operating lease (net of any incentives given to the lessee) is recognised in profit or loss on a straight-line basis over the lease term.

- C. If the Group recognises rental revenue based on a certain percentage of lessees' operating revenue, then the rent is belong to a contingent rent, which should be treated as an operating lease. The revenue will be recognised based on the receivable rents during the contract period.

(14) Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the weighted-average method. The item by item approach is used in applying the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

(15) Investments accounted for using the equity method / associates

- A. Associates are all entities over which the Group has significant influence but not control. In general, it is presumed that the investor has significant influence, if an investor holds, directly or indirectly 20 percent or more of the voting power of the investee. Investments in associates are accounted for using the equity method and are initially recognised at cost.
- B. The Group's share of its associates' post-acquisition profits or losses is recognised in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income. When the Group's share of losses in an associate equals or exceeds the Group's interest in the associate, including any other unsecured receivables, the Group does not recognise further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.
- C. When changes in an associate's equity do not arise from profit or loss or other comprehensive income of the associate and such changes do not affect the Group's ownership percentage of the associate, the Group recognises change in ownership interests in the associate in 'capital surplus' in proportion to its ownership.
- D. Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in the associates. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates are consistency with the policies adopted by the Group.
- E. When the Group disposes its investment in an associate and loses significant influence over this associate, the amounts previously recognised in other comprehensive income in relation to the associate, are reclassified to profit or loss, on the same basis as would be required if the relevant assets or liabilities were disposed of. If it retains significant influence over this associate, the amounts previously recognised in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately in accordance with the aforementioned approach.

(16) Property, plant and equipment

- A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalised.

- B. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
- C. Land is not depreciated. Other property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives. Each part of an item of property, plant and equipment with a cost that is significant in relation to the total cost of the item must be depreciated separately.
- D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end. If expectations for the assets' residual values and useful lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change.

The estimated useful lives of property, plant and equipment are as follows:

Buildings and structures (including auxiliary facilities)	3 ~ 50 years
Transportation equipment	5 years
Machinery and equipment	3 ~ 10 years
Leased assets-Machinery and equipment	0.83 ~ 50 years
Leased assets-others	0.33 ~ 25 years
Other equipment	1 ~ 50 years
Leasehold improvements	3 ~ 5 years

(17) Leasing arrangements (lessee) — right-of-use assets / lease liabilities

- A. Leases are recognised as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. For short-term leases or leases of low-value assets, lease payments are recognised as an expense on a straight-line basis over the lease term.
- B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of fixed payments, less any lease incentives receivable.

The Group subsequently measures the lease liability at amortised cost using the interest method and recognises interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognised as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.

- C. At the commencement date, the right-of-use asset is stated at cost comprising the following:
- (a) The amount of the initial measurement of lease liability;
 - (b) Any lease payments made at or before the commencement date; and
 - (c) Any initial direct costs incurred by the lessee.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognised as an adjustment to the right-of-use asset.

- D. For lease modifications that decrease the scope of the lease, the lessee shall decrease the carrying amount of the right-of-use asset and remeasure the lease liability to reflect the partial or full termination of the lease, and recognise the difference in profit or loss.

(18) Investment property

An investment property is stated initially at its cost and measured subsequently using the cost model. Except for land, investment property is depreciated on a straight-line basis over its estimated useful life of 3~55 years.

(19) Intangible assets

- A. Trademark licenses and supply rights

Separately acquired supply rights are stated at historical cost. Trademark licenses and supply rights acquired in a business combination are recognised at fair value at the acquisition date. Trademark licenses and supply rights have a finite useful life and are amortised on a straight-line basis over their estimated useful life of 13 years.

- B. Customer Relationship

Customer relationship acquired in a business combination is recognised at fair value at the acquisition date. Customer relationship has a finite useful life and is amortised on a straight-line basis over its useful life of 20 years.

- C. Goodwill

Goodwill arises in a business combination accounted for by applying the acquisition method.

(20) Impairment of non-financial assets

- A. The Group assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. Except for goodwill, when the circumstances or reasons for recognising impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased carrying amount due to reversal should not be more than what the depreciated or amortised historical cost would have been if the impairment had not been recognised.

- B. The recoverable amounts of goodwill, intangible assets with an indefinite useful life and intangible assets that have not yet been available for use are evaluated periodically. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. Impairment loss of goodwill previously recognised in profit or loss shall not be reversed in the following years.
- C. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or groups of cash-generating units, that is/are expected to benefit from the synergies of the business combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level.

(21) Borrowings

Borrowings comprise long-term and short-term bank borrowings.

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

(22) Notes and accounts payable

- A. Accounts payable are liabilities for purchases of raw materials, goods or services and notes payable are those resulting from operating and non-operating activities.
- B. The short-term notes and accounts payable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(23) Convertible bonds payable

Convertible bonds issued by the Group contain conversion options (that is, the bondholders have the right to convert the bonds into the Group's common shares by exchanging a fixed amount of cash for a fixed number of common shares), call options and put options. The Group classifies the bonds payable upon issuance as a financial asset, a financial liability or an equity instrument in accordance with the contract terms. They are accounted for as follows:

- A. The embedded call options and put options are recognised initially at net fair value as 'financial assets or financial liabilities at fair value through profit or loss'. They are subsequently remeasured and stated at fair value on each balance sheet date; the gain or loss is recognised as 'gain or loss on valuation of financial assets or financial liabilities at fair value through profit or loss'.
- B. The host contracts of bonds are initially recognised at fair value. Any difference between the initial recognition and the redemption value is accounted for as the premium or discount on bonds payable and subsequently is amortised in profit or loss as an adjustment to 'finance costs' over the period of circulation using the effective interest method.

- C. The embedded conversion options which meet the definition of an equity instrument are initially recognised in 'capital surplus-share options' at the residual amount of total issue price less the amount of financial assets or financial liabilities at fair value through profit or loss and bonds payable as stated above. Conversion options are not subsequently remeasured.
- D. Any transaction costs directly attributable to the issuance are allocated to each liability or equity component in proportion to the initial carrying amount of each abovementioned item.
- E. When bondholders exercise conversion options, the liability component of the bonds (including bonds payable and 'financial assets or financial liabilities at fair value through profit or loss') shall be remeasured on the conversion date. The issuance cost of converted common shares is the total book value of the abovementioned liability component and 'capital surplus - share options'.

(24) Derecognition of financial liabilities

A financial liability is derecognised when the obligation specified in the contract is discharged or cancelled or expires.

(25) Provisions

Provisions (including warranties and decommissioning) are recognised when the Group has a present legal or constructive obligation as a result of past events, and it is probable that an outflow of economic resources will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation on the balance sheet date, which is discounted using a pre-tax discount rate that reflects the current market assessments of the time value of money and the risks specific to the obligation. When discounting is used, the increase in the provision due to passage of time is recognised as interest expense. Provisions are not recognised for future operating losses.

(26) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognised as expense in that period when the employees render service.

B. Pensions

For defined contribution plans, the contributions are recognised as pension expense when they are due on an accrual basis. Prepaid contributions are recognised as an asset to the extent of a cash refund or a reduction in the future payments.

C. Employees' compensation and directors' and supervisors' remuneration

Employees' compensation and directors' and supervisors' remuneration are recognised as expenses and liabilities, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between

the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates. If employee compensation is distributed by shares, the Group calculates the number of shares based on the closing price at the previous day of the board meeting resolution.

(27) Employee share-based payment

- A. For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognised as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions and non-vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognised is based on the number of equity instruments that eventually vest.
- B. The grant date of the share-based payment arrangements is the date that subscription price and shares are determined.

(28) Income tax

- A. The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or items recognised directly in equity, in which cases the tax is recognised in other comprehensive income or equity.
- B. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.
- C. Deferred tax is recognised, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated balance sheet. However, the deferred tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is determined using tax rates and laws that have been

enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled.

- D. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. At each balance sheet date, unrecognised and recognised deferred tax assets are reassessed.
- E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realise the asset and settle the liability simultaneously.

(29) Dividends

Dividends are recorded in the Company's financial statements in the period in which they are approved by the Board of Directors. Cash dividends are recorded as liabilities; stock dividends are recorded as stock dividends to be distributed in the Company's financial statements in the period in which they are resolved by the Company's shareholders and are reclassified to ordinary shares on the effective date of new shares issuance.

(30) Revenue recognition

A. Sales of goods

- (a) The Group sells medical equipment, various medicines and health supplements. Sales are recognised when control of the goods has transferred, and there is no unfulfilled obligation that could affect the customer's acceptance of the goods. Delivery occurs when the goods have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the goods in accordance with the sales contract, or the Group has objective evidence that all criteria for acceptance have been satisfied.
- (b) The Group's obligation to provide maintenance and repair services for faulty goods under the standard warranty terms is recognised as a provision.
- (c) A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.
- (d) Installment sales with periodic collections of consideration
Revenue attributable to the sales price (excluding interest) is recognised on the date of sale. The sales price is the present value of consideration to be collected, calculated by discounting future payments receivable. Interest income is recognised when earned using the effective interest method.

B. Maintenance, repair, and installation service

- (a) The Group provides maintenance, repair, and installation services for medical equipment. Revenue from providing services is recognised in the accounting period in which the services are rendered. For fixed-price contracts, revenue is recognised based on the actual service provided to the end of the reporting period as a proportion of the total services to be provided. This is determined based on the actual cost spent relative to the total expected cost. The customer pays at the time specified in the payment schedule. If the services rendered exceed the payment, a contract asset is recognised. If the payments exceed the services rendered, a contract liability is recognised.
- (b) Certain customer contracts include equipment sale and installation services. In such contracts, the Group provides a significant service of integrating goods and services into a combined item, therefore the equipment and the installation service cannot be separately identified. The timing of revenue recognition is the same as that of the sale of goods.
- (c) The Group's estimate about revenue, costs and progress towards complete satisfaction of a performance obligation is subject to a revision whenever there is a change in circumstances. Any increase or decrease in revenue or costs due to an estimate revision is reflected in profit or loss during the period when the management becomes aware of the changes in circumstances.
- (d) Revenue from a service contract in which the Group bills a fixed amount based on the period of service provided is recognised at the amount to which the Group has the right to invoice.

C. Revenue from trademark licensing fee

The collection of trademark licensing fee is calculated based on a certain percentage of customer sales as negotiated by the Group and the customer. The Group recognises revenue when the performance obligation has been satisfied and the subsequent sale occurs.

D. For detailed information on rental revenue, please refer to Note 4(13).

E. Financing components

The Group adjusts the transaction prices for the time value of money if the contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year.

(31) Government grants

Government grants are recognised at their fair value only when there is reasonable assurance that the Group will comply with any conditions attached to the grants and the grants will be received. Government grants are recognised in profit or loss on a systematic basis over the periods in which the Group recognises expenses for the related costs for which the grants are intended to compensate. Government grants related to property, plant and equipment are recognised as non-current liabilities and are amortised to profit or loss over the estimated useful lives of the related

assets using the straight-line method.

(32) Business combinations

- A. The Group uses the acquisition method to account for business combinations. The consideration transferred for an acquisition is measured as the fair value of the assets transferred, liabilities incurred or assumed and equity instruments issued at the acquisition date, plus the fair value of any assets and liabilities resulting from a contingent consideration arrangement. All acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. For each business combination, the Group measures at the acquisition date components of non-controlling interests in the acquiree that are present ownership interests and entitle their holders to the proportionate share of the entity's net assets in the event of liquidation at either fair value or the present ownership instruments' proportionate share in the recognised amounts of the acquiree's identifiable net assets. All other non-controlling interests should be measured at the acquisition-date fair value.
- B. The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the fair value of any previous equity interest in the acquiree over the fair value of the identifiable assets acquired and the liabilities assumed is recorded as goodwill at the acquisition date. If the total of consideration transferred, non-controlling interest in the acquiree recognised and the fair value of previously held equity interest in the acquiree is less than the fair value of the identifiable assets acquired and the liabilities assumed, the difference is recognised directly in profit or loss on the acquisition date.

(33) Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments.

5. CRITICAL ACCOUNTING JUDGMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these consolidated financial statements requires management to make critical judgments in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year; and the related information is addressed below:

(1) Critical judgments in applying the Group's accounting policies

Except for the accounting estimates (detailed in (2) below), the management does not make any judgment that significantly affect the recognised amounts in consolidated financial statements when applying the Group's accounting policies.

(2) Critical accounting estimates and assumptions

The Group makes estimates and assumptions based on the expectation of future events that are believed to be reasonable under the circumstances at the end of the reporting period. The resulting accounting estimates might be different from the actual results. The estimates and assumptions that may significantly adjust the carrying amounts of assets and liabilities within the next financial year are addressed below:

A. Impairment assessment of tangible assets

The Group assesses impairment based on its subjective judgment and determines the separate cash flows of a specific group of assets, useful lives of assets and the future possible income and expenses arising from the assets depending on how assets are utilised and industrial characteristics. Any changes of economic circumstances or estimates due to the change of Group strategy might cause material impairment on assets in the future.

B. Impairment assessment of goodwill

The impairment assessment of goodwill relies on the Group's subjective judgment, including identifying cash-generating units, allocating assets and liabilities as well as goodwill to related cash-generating units, and determining the recoverable amounts of related cash-generating units.

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) Cash and cash equivalents

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Cash on hand	\$ 1,425	\$ 1,207
Checking accounts and demand deposits	1,715,956	1,421,642
Time deposits	174,000	50,000
	<u>\$ 1,891,381</u>	<u>\$ 1,472,849</u>

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

B. The Group classified restricted cash and cash equivalents pledged to others for the performance of contract and bank borrowings as other non-current assets. Please refer to Note 8 for details.

(2) Financial assets at fair value through profit or loss

<u>Items</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Current items:		
Financial assets mandatorily measured at fair value through profit or loss		
Listed stocks	\$ 78,280	\$ 68,785
Valuation adjustment	(8,900)	(26,874)
	<u>\$ 69,380</u>	<u>\$ 41,911</u>

<u>Items</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Non-current items:		
Financial assets mandatorily measured at fair value through profit or loss		
Unlisted stocks	\$ 59,960	\$ 59,960
Privately offered funds	6,000	-
Non-hedging derivatives (Redemption rights to the fourth domestic issuance of secured convertible corporate bonds)	909	1,050
Valuation adjustment	920	(750)
	<u>\$ 67,789</u>	<u>\$ 60,260</u>

For the years ended December 31, 2023 and 2022, net gain (loss) on financial assets at fair value through profit or loss were \$13,089 and (\$17,992), respectively, shown as ‘other gains and losses’.

(3) Financial assets at fair value through other comprehensive income

<u>Items</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Non-current items:		
Listed stocks	\$ 340,215	\$ 340,215
Unlisted stocks	41,400	41,400
Valuation adjustment	(344,656)	(352,037)
	<u>\$ 36,959</u>	<u>\$ 29,578</u>

A. The Group has elected to classify equity investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments amounted to \$36,959 and \$29,578 as at December 31, 2023 and 2022, respectively.

B. The Group recognised \$7,381 and (\$1,869) in other comprehensive income (loss) for fair value change for the years ended December 31, 2023 and 2022, respectively.

(4) Financial assets at amortised cost

<u>Items</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Current items:		
Time deposits with maturity over three months	<u>\$ 66,089</u>	<u>\$ 205,144</u>
Non-current items:		
Time deposits with maturity over three months and a year	<u>\$ 199,745</u>	<u>\$ 204,337</u>

A. Amounts recognised in profit or loss in relation to financial assets at amortised cost are listed below:

	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Interest income	<u>\$ 5,284</u>	<u>\$ 3,447</u>

- B. The Group's financial assets at amortised cost are time deposits in banks. The Group transacted with banks which have high credit rating.
- C. Details of the Group's certain financial assets at amortised cost pledged to others as collateral are provided in Note 8.

(5) Notes and accounts receivable (including long-term notes and accounts receivable)

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Notes receivable	\$ 7,051	\$ 10,306
Installment notes receivable	32,384	36,668
Less: Unrealised interest revenue-installment notes receivable	(597)	(652)
	38,838	46,322
Less: Allowance for doubtful accounts	(1)	-
	<u>\$ 38,837</u>	<u>\$ 46,322</u>
	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Accounts receivable	\$ 705,017	\$ 538,378
Installment accounts receivable	30,423	45,356
Less: Unrealised interest revenue-installment accounts receivable	(6,315)	(7,172)
Lease payments receivable	23,171	14,063
Less: Unearned finance income of finance lease	(7,408)	(4,438)
	744,888	586,187
Less: Allowance for doubtful accounts	(6,531)	(4,759)
	<u>\$ 738,357</u>	<u>\$ 581,428</u>

- A. The Group sold equipment under installment payment, subleased right-of-use asset - buildings under finance lease and recognised installment receivables with maturity over a year as long-term installment receivables (shown as 'long-term notes and accounts receivable'). At the balance sheet date, the Group's receivables arising from installment payments and financial lease are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Total long-term installment notes receivable	\$ 10,809	\$ 8,083
Less: Unrealised interest revenue - long-term installment notes receivable	(188)	(121)
Total long-term installment accounts receivable	161,308	187,693
Less: Unrealised interest revenue - long-term installment accounts receivable	(19,700)	(25,410)
Long-term lease payments receivable	142,778	86,534
Less: Unearned finance income of finance lease	(27,708)	(16,216)
	267,299	240,563
Less: Allowance for doubtful accounts	-	-
	<u>\$ 267,299</u>	<u>\$ 240,563</u>

- B. Reconciliation of the undiscounted lease payments of the right-of-use asset - buildings sublease and the net investment under the finance lease is provided as follows:

	<u>December 31, 2023</u>		
	<u>Undiscounted lease payments</u>	<u>Unearned finance income</u>	<u>Net investment in the lease</u>
<u>Current</u>			
Not later than one year	\$ 23,171	(\$ 7,408)	\$ 15,763
<u>Non-current</u>			
Over one year	<u>142,778</u>	<u>(27,708)</u>	<u>115,070</u>
	<u>\$ 165,949</u>	<u>(\$ 35,116)</u>	<u>\$ 130,833</u>
	<u>December 31, 2022</u>		
	<u>Undiscounted lease payments</u>	<u>Unearned finance income</u>	<u>Net investment in the lease</u>
<u>Current</u>			
Not later than one year	\$ 14,063	(\$ 4,438)	\$ 9,625
<u>Non-current</u>			
Over one year	<u>86,534</u>	<u>(16,216)</u>	<u>70,318</u>
	<u>\$ 100,597</u>	<u>(\$ 20,654)</u>	<u>\$ 79,943</u>

C. The ageing analysis of notes and accounts receivable is as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Not past due	\$ 983,916	\$ 842,069
Up to 1 month	30,133	17,862
Up to 2 months	18,964	3,926
Up to 3 months	2,952	3,912
Up to 4 months	2,680	917
Up to 5 months	1,893	912
Up to 6 months	-	534
Over 6 months	10,487	2,940
	<u>\$ 1,051,025</u>	<u>\$ 873,072</u>

The above receivables included the receivables generated from the Group's business activities for the sales and lease of medical equipment and the ageing analysis was based on past due month.

D. The Group expected to recover installment notes and accounts receivable as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Not later than one year	\$ 55,895	\$ 74,200
Over one year	152,229	170,245
	<u>\$ 208,124</u>	<u>\$ 244,445</u>

E. As of December 31, 2023, December 31, 2022 and January 1, 2022, the balances of receivables (including long-term receivables) from contracts with customers amounted to \$673,938, \$552,309, and \$412,801, respectively.

F. For the years ended December 31, 2023 and 2022, the interest income (shown as 'others' in 'operating revenue') for installment notes and accounts receivable (including long-term) is recognised in profit or loss of \$8,141 and \$6,997, respectively.

G. Information relating to credit risk of notes and accounts receivable is provided in Note 12(2).

(6) Inventories

	<u>December 31, 2023</u>		
	<u>Cost</u>	<u>Allowance for valuation loss</u>	<u>Book value</u>
Merchandise inventories	\$ 612,554	(\$ 76,318)	\$ 536,236
Inventory in transit	69,240	-	69,240
	<u>\$ 681,794</u>	<u>(\$ 76,318)</u>	<u>\$ 605,476</u>

	<u>December 31, 2022</u>		
	<u>Cost</u>	<u>Allowance for valuation loss</u>	<u>Book value</u>
Merchandise inventories	\$ 488,433	(\$ 65,636)	\$ 422,797
Inventory in transit	105,124	-	105,124
	<u>\$ 593,557</u>	<u>(\$ 65,636)</u>	<u>\$ 527,921</u>

- A. The abovementioned inventories were not secured or pledged to others.
- B. The cost of inventories recognised as expense and operating costs for the year:

	Years ended December 31,	
	2023	2022
Cost of goods sold	\$ 1,799,460	\$ 1,193,193
Repair supplies	86,511	68,960
Loss on decline in market value and obsolescence	10,682	7,675
Cost of inventories	1,896,653	1,269,828
Cost of rental	761,580	691,225
Cost of services	150,744	110,985
Total operating costs	<u>\$ 2,808,977</u>	<u>\$ 2,072,038</u>

(7) Prepayments

	December 31, 2023	December 31, 2022
Prepayments to suppliers	\$ 547,899	\$ 513,631
Excess business tax paid	15,206	42,277
Others	25,341	20,583
	<u>\$ 588,446</u>	<u>\$ 576,491</u>

(8) Investments accounted for using equity method

	December 31, 2023		December 31, 2022	
	Ownership %	Book value	Ownership %	Book value
<u>Associates</u>				
CHENG-HSIN Biotechnology Co., Ltd.	40%	<u>\$ 9,911</u>	40%	<u>\$ 8,307</u>

- A. The summarised financial information of the associate that is not material to the Group is as follows:

	Years ended December 31,	
	2023	2022
Profit (loss) for the year	\$ 1,604	(\$ 334)
Other comprehensive income, net of tax	-	-
Total comprehensive income (loss) for the year	<u>\$ 1,604</u>	<u>(\$ 334)</u>

- B. The Group is the single largest shareholder of CHENG-HSIN Biotechnology Co., Ltd with a 40% equity interest. Given that the remaining 60% equity interest in CHENG-HSIN Biotechnology Co., Ltd is held by other few investors that are related parties of another joint venture group, which indicates that the Group has no current ability to direct the relevant activities of CHENG-HSIN Biotechnology Co., Ltd, the Group has no control, but only has significant influence, over the investee.

(9) Property, plant and equipment

	Land	Buildings and structures	Transportation equipment	Machinery and equipment	Leased assets- machinery and equipment	Leased assets- others	Leasehold improvements	Other equipment	Construction in progress and equipment under acceptance	Total
<u>At January 1, 2023</u>										
Cost	\$ 759,015	\$ 525,872	\$ 1,524	\$ 45,283	\$ 6,242,020	\$ 1,444,704	\$ 25,714	\$ 42,260	\$ 817,654	\$ 9,904,046
Accumulated depreciation and impairment	-	(44,254)	(1,359)	(24,192)	(3,263,798)	(718,984)	(4,216)	(22,575)	-	(4,079,378)
	<u>\$ 759,015</u>	<u>\$ 481,618</u>	<u>\$ 165</u>	<u>\$ 21,091</u>	<u>\$ 2,978,222</u>	<u>\$ 725,720</u>	<u>\$ 21,498</u>	<u>\$ 19,685</u>	<u>\$ 817,654</u>	<u>\$ 5,824,668</u>
<u>2023</u>										
Opening net book										
amount as at January 1	\$ 759,015	\$ 481,618	\$ 165	\$ 21,091	\$ 2,978,222	\$ 725,720	\$ 21,498	\$ 19,685	\$ 817,654	\$ 5,824,668
Additions (Note 1)	-	115,378	1,755	1,440	175,700	55,673	9,675	22,376	225,751	607,748
Disposals	-	-	(41)	-	-	(91)	(1,470)	(797)	-	(2,399)
Depreciation charge	-	(40,838)	(197)	(11,342)	(371,954)	(97,348)	(4,966)	(5,367)	-	(532,012)
Reclassifications (Note 2)	-	523,395	-	4,754	(1,305)	1,416	720	796	(508,688)	21,088
Net exchange differences	-	-	-	-	(1,652)	(30)	(4)	-	(1,160)	(2,846)
Closing net book amount										
as at December 31	<u>\$ 759,015</u>	<u>\$ 1,079,553</u>	<u>\$ 1,682</u>	<u>\$ 15,943</u>	<u>\$ 2,779,011</u>	<u>\$ 685,340</u>	<u>\$ 25,453</u>	<u>\$ 36,693</u>	<u>\$ 533,557</u>	<u>\$ 5,916,247</u>
<u>At December 31, 2023</u>										
Cost	\$ 759,015	\$ 1,164,644	\$ 2,459	\$ 45,193	\$ 6,159,872	\$ 1,471,542	\$ 33,076	\$ 64,260	\$ 533,557	\$10,233,618
Accumulated depreciation and impairment	-	(85,091)	(777)	(29,250)	(3,380,861)	(786,202)	(7,623)	(27,567)	-	(4,317,371)
	<u>\$ 759,015</u>	<u>\$ 1,079,553</u>	<u>\$ 1,682</u>	<u>\$ 15,943</u>	<u>\$ 2,779,011</u>	<u>\$ 685,340</u>	<u>\$ 25,453</u>	<u>\$ 36,693</u>	<u>\$ 533,557</u>	<u>\$ 5,916,247</u>

Note 1: The acquisition of property, plant and equipment includes the beginning and ending balances of payable on machinery and equipment in the amounts of \$12,565 and \$67,023, respectively, additions to decommissioning cost in the amount of \$1,200 (at the same time, additions to decommissioning liabilities in the amounts of \$1,200 which was shown as “Non-current provisions”), capitalisation of amortised government granted loan interest expense of \$2,418 (at the same time, additions to long-term borrowings of \$2,418) and the cash payment in the amount of \$549,672.

Note 2: Reclassifications with no cash flow effect are as follows:

- Inventories transferred to property, plant and equipment amounted to \$1,249.
- Property, plant and equipment transferred to inventories amounted to \$2,114.
- Property, plant and equipment transferred to expenses amounted to \$488.
- Other non-current assets transferred to property, plant and equipment amounted to \$22,441.

	Land	Buildings and structures	Transportation equipment	Machinery and equipment	Leased assets-machinery and equipment	Leased assets-others	Leasehold improvements	Other equipment	Construction in progress and equipment under acceptance	Total
<u>At January 1, 2022</u>										
Cost	\$ 759,015	\$ 521,087	\$ 7,147	\$ 137,334	\$ 5,111,200	\$ 974,970	\$ 12,766	\$ 42,240	\$ 1,774,840	\$ 9,340,599
Accumulated depreciation and impairment	-	(29,585)	(6,938)	(110,537)	(3,065,474)	(679,026)	(1,107)	(19,330)	-	(3,911,997)
	<u>\$ 759,015</u>	<u>\$ 491,502</u>	<u>\$ 209</u>	<u>\$ 26,797</u>	<u>\$ 2,045,726</u>	<u>\$ 295,944</u>	<u>\$ 11,659</u>	<u>\$ 22,910</u>	<u>\$ 1,774,840</u>	<u>\$ 5,428,602</u>
<u>2022</u>										
Opening net book amount as at January 1	\$ 759,015	\$ 491,502	\$ 209	\$ 26,797	\$ 2,045,726	\$ 295,944	\$ 11,659	\$ 22,910	\$ 1,774,840	\$ 5,428,602
Additions (Note 1)	-	4,785	-	2,515	69,355	121,417	10,337	5,217	437,167	650,793
Disposals	-	-	-	-	(51,803)	(2)	-	(213)	-	(52,018)
Depreciation charge	-	(14,669)	(45)	(6,403)	(336,122)	(77,512)	(3,095)	(5,231)	-	(443,077)
Reclassifications (Note 2)	-	-	-	(1,818)	1,250,502	385,848	2,594	(2,999)	(1,394,332)	239,795
Net exchange differences	-	-	1	-	564	25	3	1	(21)	573
Closing net book amount as at December 31	<u>\$ 759,015</u>	<u>\$ 481,618</u>	<u>\$ 165</u>	<u>\$ 21,091</u>	<u>\$ 2,978,222</u>	<u>\$ 725,720</u>	<u>\$ 21,498</u>	<u>\$ 19,685</u>	<u>\$ 817,654</u>	<u>\$ 5,824,668</u>
<u>At December 31, 2022</u>										
Cost	\$ 759,015	\$ 525,872	\$ 1,524	\$ 45,283	\$ 6,242,020	\$ 1,444,704	\$ 25,714	\$ 42,260	\$ 817,654	\$ 9,904,046
Accumulated depreciation and impairment	-	(44,254)	(1,359)	(24,192)	(3,263,798)	(718,984)	(4,216)	(22,575)	-	(4,079,378)
	<u>\$ 759,015</u>	<u>\$ 481,618</u>	<u>\$ 165</u>	<u>\$ 21,091</u>	<u>\$ 2,978,222</u>	<u>\$ 725,720</u>	<u>\$ 21,498</u>	<u>\$ 19,685</u>	<u>\$ 817,654</u>	<u>\$ 5,824,668</u>

Note 1: The acquisition of property, plant and equipment includes the beginning and ending balances of payable on machinery and equipment in the amounts of \$49,405 and \$12,565, respectively, additions to decommissioning cost in the amount of \$5,000 (at the same time, additions to decommissioning liabilities in the amounts of \$5,000 which was shown as “Non-current provisions”), and the cash payment in the amount of \$682,633.

Note 2: Reclassifications with no cash flow effect are as follows:

- Inventories transferred to property, plant and equipment amounted to \$4,804.
- Property, plant and equipment transferred to inventories amounted to \$1,818.
- Property, plant and equipment transferred to expenses amounted to \$1,673.
- Other non-current assets transferred to property, plant and equipment amounted to \$238,482.

- A. Amount of borrowing costs capitalised as part of property, plant and equipment and prepayments for business facilities (shown as ‘other non-current assets’) and the range of the interest rates for such capitalisation are as follows:

	Years ended December 31,	
	2023	2022
Amount capitalised	\$ 8,697	\$ 15,408
Range of the interest rates for capitalisation	0.60%~6.40%	0.10%~4.25%

- B. Information about the property, plant and equipment that were pledged to others as collateral is provided in Note 8.

(10) Leasing arrangements-lessee

- A. The Group leases various assets including land, buildings, machinery and equipment and business vehicles. Rental contracts are typically made for periods of 1 to 19 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose covenants, but leased assets may not be used as security for borrowing purposes.
- B. Short-term leases with a lease term of 12 months or less comprise business vehicles, offices and dormitories. Low-value assets comprise copy machines.
- C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

	Book value	
	December 31, 2023	December 31, 2022
Land	\$ 38,594	\$ 41,006
Buildings	65,388	56,223
Transportation equipment (Business vehicles)	5,386	7,064
Machinery and equipment	1,067	-
	<u>\$ 110,435</u>	<u>\$ 104,293</u>

	Depreciation charge	
	Years ended December 31,	
	2023	2022
Land	\$ 2,412	\$ 2,412
Buildings	14,070	9,210
Transportation equipment (Business vehicles)	3,955	3,956
Machinery and equipment	133	-
	<u>\$ 20,570</u>	<u>\$ 15,578</u>

- D. For the years ended December 31, 2023 and 2022, the additions to right-of-use assets were \$95,280 and \$81,680, respectively.

E. The information on profit and loss accounts relating to lease contracts is as follows:

	Years ended December 31,	
	2023	2022
<u>Items affecting profit or loss</u>		
Interest expense on lease liabilities	(\$ 3,949)	(\$ 2,713)
Expense on short-term lease contracts	(1,376)	(4,620)
Expense on leases of low-value assets	(111)	(109)
Finance income from sublease of right-of-use assets (shown as 'interest income')	6,310	3,959
Gain on lease modification (shown as 'other gains and losses')	162	-

F. Reconciliation of the undiscounted lease payments of the right-of-use asset - buildings sublease and the net investment under the finance lease is provided in Note 6(5)B.

G. For the years ended December 31, 2023 and 2022, the Group's total cash outflow for leases were \$38,946 and \$31,179, respectively.

H. As of December 31, 2023 and 2022, the Group's undiscounted lease liabilities of housing leases that have not yet started but have been committed were \$15,655 and \$12,100, respectively.

(11) Leasing arrangements-lessor

A. The Group leases various assets including buildings, machinery and other equipment. Rental contracts are typically made for periods of 1 and 25 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. To protect the lessor's ownership rights on the leased assets, leased assets may not be used as security for borrowing purposes.

B. The Group leases machinery and equipment, other equipment and right-of-use assets - buildings under a finance lease. Based on the terms of the lease contract, the ownership of machinery and other equipment will be transferred to lessees when the leases expire. Information on profit or loss in relation to lease contracts is as follows:

	Years ended December 31,	
	2023	2022
Sales profit	\$ 724	\$ 41
Finance income from the net investment in the finance lease (shown as 'others' in 'operating revenue')	651	1,000
Finance income from sublease of right-of-use assets (shown as 'interest income')	6,310	3,959

- C. The maturity analysis of the undiscounted lease payments (including related parties) in the finance lease is as follows:

	<u>December 31, 2023</u>		<u>December 31, 2022</u>
2024	\$ 44,174	2023	\$ 41,070
2025	24,549	2024	24,014
2026	22,736	2025	14,416
2027	21,010	2026	12,603
2028	19,420	2027	10,877
2029	18,465	2028	9,934
2030 and onwards	45,848	2029 and onwards	26,979
	<u>\$ 196,202</u>		<u>\$ 139,893</u>

- D. Reconciliation of the undiscounted lease payments and the net investment in the finance lease is provided in Notes 6(5) and (7).

- E. Gain arising from operating lease agreements for the years ended December 31, 2023 and 2022 are as follows:

	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Rent income	\$ 60,733	\$ 57,540
Contingent rental revenue	\$ 1,113,766	\$ 1,076,980

- F. The maturity analysis of the lease payments under the operating leases is as follows:

	<u>December 31, 2023</u>		<u>December 31, 2022</u>
2024	\$ 56,963	2023	\$ 55,314
2025	52,746	2024	50,866
2026	51,512	2025	48,517
2027	2,885	2026	47,284
2028	1,257	2027	370
2029	-	2028	-
2030 and onwards	-	2029 and onwards	-
	<u>\$ 165,363</u>		<u>\$ 202,351</u>

(12) Investment property

	<u>Land</u>	<u>Buildings and structures</u>	<u>Total</u>
<u>At January 1, 2023</u>			
Cost	\$ 948,656	\$ 707,477	\$1,656,133
Accumulated depreciation and impairment	-	(227,090)	(227,090)
	<u>\$ 948,656</u>	<u>\$ 480,387</u>	<u>\$1,429,043</u>
<u>2023</u>			
Opening net book amount as at January 1	\$ 948,656	\$ 480,387	\$1,429,043
Additions from acquisitions (Note 1)	26,697	2,770	29,467
Acquired from business combinations	86,653	19,580	106,233
Reclassifications (Note 2)	5,900	-	5,900
Depreciation charge	-	(19,981)	(19,981)
Net exchange differences	-	(1,358)	(1,358)
Closing net book amount as at December 31	<u>\$ 1,067,906</u>	<u>\$ 481,398</u>	<u>\$1,549,304</u>
<u>At December 31, 2023</u>			
Cost	\$ 1,067,906	\$ 728,382	\$1,796,288
Accumulated depreciation and impairment	-	(246,984)	(246,984)
	<u>\$ 1,067,906</u>	<u>\$ 481,398</u>	<u>\$1,549,304</u>

Note 1: The acquisition of investment property includes the beginning and ending balances of payable on machinery and equipment in the amounts of \$952 and \$1,029, respectively, and the cash payment in the amount of \$29,390.

Note 2: Reclassifications with no cash flow effects are as follows:

Other non-current assets transferred to investment property amounted to \$5,900.

	<u>Land</u>	<u>Buildings and structures</u>	<u>Total</u>
<u>At January 1, 2022</u>			
Cost	\$ 994,284	\$ 727,912	\$1,722,196
Accumulated depreciation and impairment	<u>-</u>	<u>(216,739)</u>	<u>(216,739)</u>
	<u>\$ 994,284</u>	<u>\$ 511,173</u>	<u>\$1,505,457</u>
<u>2022</u>			
Opening net book amount as at January 1	\$ 994,284	\$ 511,173	\$1,505,457
Additions - from subsequent expenditures (Note)	-	1,358	1,358
Disposals	(45,628)	(13,797)	(59,425)
Depreciation charge	-	(19,487)	(19,487)
Net exchange differences	<u>-</u>	<u>1,140</u>	<u>1,140</u>
Closing net book amount as at December 31	<u>\$ 948,656</u>	<u>\$ 480,387</u>	<u>\$1,429,043</u>
<u>At December 31, 2022</u>			
Cost	\$ 948,656	\$ 707,477	\$1,656,133
Accumulated depreciation and impairment	<u>-</u>	<u>(227,090)</u>	<u>(227,090)</u>
	<u>\$ 948,656</u>	<u>\$ 480,387</u>	<u>\$1,429,043</u>

Note: The acquisition of investment property includes the beginning and ending balances of payable on machinery and equipment in the amounts of \$1,671 and \$952, respectively, and the cash payment in the amount of \$2,077.

- A. Rental income from lease of the investment property and direct operating expenses arising from investment property are shown below:

	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Rental income from the lease of the investment property	<u>\$ 60,592</u>	<u>\$ 57,435</u>
Direct operating expenses arising from the investment property that generated rental income during the year	<u>\$ 24,529</u>	<u>\$ 23,004</u>
Direct operating expenses arising from the investment property that did not generate rental income during the year	<u>\$ -</u>	<u>\$ 1,304</u>

- B. As of December 31, 2023 and 2022, the fair value of the investment property held by the Group amounted to \$1,957,944 and \$1,791,459, respectively. The fair value was valued by adopting the transaction prices of similar property or valued by independent appraisers who adopted comparison approach and land development analysis approach to evaluate the land, assessed the building based on cost method, and considered weights on aforementioned costs to calculate the fair value.
- C. Information about the investment property that was pledged to others as collateral is provided in Note 8.

(13) Intangible assets

	<u>Trademark licenses</u>	<u>Supply rights</u>	<u>Goodwill</u>	<u>Other</u>	<u>Total</u>
<u>At January 1, 2023</u>					
Cost	\$ 130,135	\$ 144,438	\$ 361,985	\$ -	\$ 636,558
Accumulated amortisation	(12,513)	(13,888)	-	-	(26,401)
	<u>\$ 117,622</u>	<u>\$ 130,550</u>	<u>\$ 361,985</u>	<u>\$ -</u>	<u>\$ 610,157</u>
<u>2023</u>					
Opening net book amount as at January 1	\$ 117,622	\$ 130,550	\$ 361,985	\$ -	\$ 610,157
Additions - acquired seperately	-	26,000	-	-	26,000
Additions - acquired through business combinations	-	-	15,869	785	16,654
Amortisation charge	(10,011)	(11,610)	-	(40)	(21,661)
Closing net book amount as at December 31	<u>\$ 107,611</u>	<u>\$ 144,940</u>	<u>\$ 377,854</u>	<u>\$ 745</u>	<u>\$ 631,150</u>
<u>At December 31, 2023</u>					
Cost	\$ 130,135	\$ 170,438	\$ 377,854	\$ 785	\$ 679,212
Accumulated amortisation	(22,524)	(25,498)	-	(40)	(48,062)
	<u>\$ 107,611</u>	<u>\$ 144,940</u>	<u>\$ 377,854</u>	<u>\$ 745</u>	<u>\$ 631,150</u>

	<u>Trademark licenses</u>	<u>Supply rights</u>	<u>Goodwill</u>	<u>Total</u>
<u>At January 1, 2022</u>				
Cost	\$ 130,135	\$ 144,438	\$ 361,985	\$ 636,558
Accumulated amortisation	(<u>2,502</u>)	(<u>2,778</u>)	-	(<u>5,280</u>)
	<u>\$ 127,633</u>	<u>\$ 141,660</u>	<u>\$ 361,985</u>	<u>\$ 631,278</u>
<u>2022</u>				
Opening net book amount as at January 1	\$ 127,633	\$ 141,660	\$ 361,985	\$ 631,278
Amortisation charge	(<u>10,011</u>)	(<u>11,110</u>)	-	(<u>21,121</u>)
Closing net book amount as at December 31	<u>\$ 117,622</u>	<u>\$ 130,550</u>	<u>\$ 361,985</u>	<u>\$ 610,157</u>
<u>At December 31, 2022</u>				
Cost	\$ 130,135	\$ 144,438	\$ 361,985	\$ 636,558
Accumulated amortisation	(<u>12,513</u>)	(<u>13,888</u>)	-	(<u>26,401</u>)
	<u>\$ 117,622</u>	<u>\$ 130,550</u>	<u>\$ 361,985</u>	<u>\$ 610,157</u>

A. Details of amortisation on intangible assets are as follows:

	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Selling expenses	<u>\$ 21,661</u>	<u>\$ 21,121</u>

B. Goodwill is allocated as follows to the Group's cash-generating units:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Treasure of Health Co., Ltd.	\$ 202,834	\$ 202,834
Hsing-Yeh Biotechnology Co., Ltd.	150,617	150,617
Others	<u>24,403</u>	<u>8,534</u>
	<u>\$ 377,854</u>	<u>\$ 361,985</u>

C. Goodwill is allocated to the Group's cash-generating units. The recoverable amount of all cash-generating units has been determined based on value-in-use calculations and fair value, net of disposal cost. These calculations use pre-tax cash flow projections based on financial budgets approved by the management covering a five-year period.

D. As of December 31, 2023, the Group's goodwill arose from business combination amounting to \$377,854, consisting of benefits from expected operating revenue growth of acquired companies. In accordance with IAS 36, goodwill acquired from business combination shall be tested for impairment at least every year and where there is any indication of impairment. The impairment testing on the goodwill as of December 31, 2023 and 2022 is as follows:

For the impairment testing of goodwill, goodwill acquired in a business combination is allocated to each of the cash-generating units that are expected to benefit from the synergies of the business combination. Each company may be a cash-generating unit which can

generate independent cash flows. Therefore, the impairment of goodwill is assessed by calculating the difference between the recoverable amount and the carrying amount of net assets of each company.

The Group used value-in-use calculated by external appraiser as the recoverable amount of goodwill arising from Treasure of Health Co., Ltd. and Hsing-Yeh Biotechnology Co., Ltd. No impairment loss occurred as of December 31, 2023 and 2022 as the recoverable amount was higher than the carrying amount. The key assumptions used by the external appraiser in calculating value-in-use are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Growth rate	2.60%	2.18%
Discount rate	7.49%~8.02%	8.19%~11.08%

The Group used the value-in-use as the recoverable amount of goodwill arising from the cash-generating units other than Treasure of Health Co., Ltd. and Hsing-Yeh Biotechnology Co., Ltd. as of December 31, 2023 and 2022. No impairment loss occurred as the recoverable amount was higher than the carrying amount. The key assumptions used for value-in-use calculations are operating profit margin and discount rate.

Management determined budgeted gross margin based on past performance and their expectations of market development. The weighted average growth rates used are consistent with the projection included in industry reports. The discount rates used are pre-tax and reflected specific risks relating to the relevant operating segments.

(14) Other non-current assets

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Guarantee deposits paid	\$ 319,068	\$ 265,118
Prepayments for investment	-	12,302
Prepayments for equipment	23,683	32,899
Restricted bank deposits	4,736	11,060
Deferred expenses	1,065	531
	<u>\$ 348,552</u>	<u>\$ 321,910</u>

Information about the restricted bank deposits that were pledged to others as collateral is provided in Note 8.

(15) Short-term borrowings

<u>Type of borrowings</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Bank borrowings		
Unsecured borrowings	<u>\$ 359,075</u>	<u>\$ 339,545</u>
Interest rate range	<u>1.71%~6.56%</u>	<u>1.42%~5.16%</u>

(16) Bonds payable

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Bonds payable	\$ 1,331,902	\$ 1,537,875
Less: Discount on bonds payable	(14,836)	(27,851)
	1,317,066	1,510,024
Less: Current portion or exercise of put options	-	-
	<u>\$ 1,317,066</u>	<u>\$ 1,510,024</u>

A. The terms of the fourth domestic secured convertible bonds issued by the Company are as follows:

- (a) The Company issued the fourth domestic secured convertible bonds totaling \$1,515,000 with zero coupon rate which were issued at a 101% premium of the total face value of \$1,500,000 as approved by the regulatory authority. The bonds mature five years from the issue date (August 4, 2020 ~ August 4, 2025) and will be redeemed in cash at 102.525% of face value at the maturity date. The bonds were listed on the Taipei Exchange on August 4, 2020.
- (b) The bondholders have the right to request TDCC through the security dealers for conversion of the bonds into common shares of the Company during the period from the date after three months of the bonds issue to the maturity date, except for the stop transfer period as specified in the terms of the bonds or the laws/regulations. The rights and obligations of the new shares converted from the bonds are the same as the issued and outstanding common shares.
- (c) The conversion price of the bonds is set up based on the pricing model in the terms of the bonds, and is subject to adjustments if the condition of the anti-dilution provisions occurs subsequently. The conversion price on the issue date is NT\$53.9 (in dollars). On July 18, 2023, July 19, 2022, November 29, 2021 and August 3, 2021, the Company adjusted the conversion price per share to NT\$46.9, NT\$48.4, NT\$50.9 and NT\$51.0 (in dollars), respectively, according to the rules described above.
- (d) The Company may repurchase all the bonds outstanding in cash at the bonds' face value at any time after the following events occur: (i) the closing price of the Company's common shares is above the then conversion price by 30% for 30 consecutive trading days during the period from the date after three month of the bonds issue to 40 days before the maturity date, or (ii) the outstanding balance of the bonds is less than 10% of total initial issue amount during the period from the date after one months of the bonds issue to 40 days before the maturity date.
- (e) Under the terms of the bonds, all bonds redeemed (including bonds repurchased from the Taipei Exchange), matured and converted are retired and not to be re-issued; all rights and obligations attached to the bonds are also extinguished.

- (f) As of December 31, 2023, the bonds totaling \$200,900 (face value) had been converted into 4,193 thousand shares of common stock.
- (g) Regarding the fourth issuance of secured convertible bonds, the equity conversion options amounting to \$21,955 were separated from the liability component and were recognised in ‘capital surplus - others’ in accordance with IAS 32 as of December 31, 2023. The call options embedded in bonds payable were separated from their host contracts and were recognised in ‘financial assets or liabilities at fair value through profit or loss’ in net amount in accordance with IFRS 9 because the economic characteristics and risks of the embedded derivatives were not closely related to those of the host contracts. As of December 31, 2023, the effective interest rate of the bonds payable after such separation was 0.7077%.

B. There were no assets pledged as collateral for the fourth domestic bonds.

(17) Long-term borrowings

<u>Type of borrowings</u>	<u>Borrowing period</u>	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Bank borrowings			
Secured borrowings	2018.3~2042.2	\$ 2,573,829	\$ 2,405,211
Unsecured borrowings	2018.11~2029.12	<u>695,650</u>	<u>575,082</u>
		3,269,479	2,980,293
Less: Long-term borrowings, current portion		(<u>202,546</u>)	(<u>67,020</u>)
		<u>\$ 3,066,933</u>	<u>\$ 2,913,273</u>
Interest rate range		<u>0.85%~3.85%</u>	<u>0.60%~4.05%</u>

A. The subsidiary of the Company, Shin-Ho Instruments Co., Ltd., entered into a borrowing contract with Chinatrust Commercial Bank. Guarantees were provided by the Company jointly for the duration of this borrowing or before the debts of this borrowing are fully paid. In addition, the subsidiary started to provide collateral with Chinatrust Commercial Bank after the completion of the building construction and before the operation of the machinery and equipment.

- (a) The subsidiary of the Company, Shin-Ho Instruments Co., Ltd., met the common qualifications of the “Action Plan for Welcoming Overseas Taiwanese Businesses to Return to Invest in Taiwan” of the National Development Council of the Executive Yuan and the specific qualifications of “Manufacturing industry - enterprise whose certain production lines for investment/expansion must have smart technology elements or smart functions and belongs to 5+2 Industrial Innovation”. The letter of approval for the qualification of Taiwanese businesses was issued by the Ministry of Economic Affairs.
- (b) Shin-Ho Instruments Co., Ltd. applied for a borrowing with the “Action Plan for Welcoming Overseas Taiwanese Businesses to Return to Invest in Taiwan”. The government provided grants on the borrowing interest rate. The borrowing interest rate

was 0.1%~0.85% during the granting period. The granting period would end in December 2026 and the borrowing interest rate would be 1.345%~2.095% starting from January 2027. In addition, the subsidiary also obtained a grace period of 24 months for principal repayment. The grace period would end in December 2023 and Shin-Ho Instruments Co., Ltd. would start to repay the principal from January 2024.

- (c) Income from long-term deferred revenue - government grants recognised for the current December 31, 2023 and 2022 was \$31,436 and \$26,857 (shown as 'other non-current liabilities').
 - (d) Income from long-term deferred revenue-government grants is related to property, plant and equipment and is recognised in profit or loss on a straight-line basis over the useful lives of related assets. For the years ended December 31, 2023 and 2022, the Group recognised government grant income \$856 and \$0(shown as 'other gain and losses'), respectively.
- B. On September 21, 2022, the Company and its subsidiary, Tomorrow Medical System Co., Ltd. signed a syndicated loan agreement in the amount of \$2,580,000 with syndicate of banks including First Commercial Bank, in order to repay the Group's existing financial liabilities and increase the working capital. In accordance with the syndicated loan agreement, the loan can be redrawn within the contract period. For each drawdown, the term shall not exceed 6 months and the amount of drawdown shall not be less than 50 million. For the amount that has not been paid at maturity, there is no need for the part of the same amount to make an additional procedure of remittance and loan. Therefore, the abovementioned financing will be listed as long-term borrowings and agreed to the following terms:
- (a) All the credit amounts which obtained according to the contract shall be used for the credit purposes specified in the contract.
 - (b) The Company will periodically issue a financial assurance letter to the banks, indicating whether the Company has achieved the required financial ratios based on the annual and semi-annual consolidated financial statements as follows:
 - i. Current ratio must be 100% or higher.
 - ii. Debt ratio must equal to or less than 170%.
 - iii. Interest coverage ratio must be 3 or higher.
 - iv. Tangible net assets must be \$4,000,000 or higher.

If the Company fails to meet any of the requirements stated above, remedial measures, such as capital increase, must be taken to address the issue before the financial reporting date of the next annual or half-year consolidated financial statements. If the issue is resolved with the remedial measures, it is not considered a breach of contract. However, the Company is required to pay a fee, equal to 0.1% of the unpaid principal balance on the audit date, to the agency bank, who will distribute this fee among the syndicate lenders.

- (c) The Company shall maintain directly/ indirectly a 100% equity interest in Chiu Ho Medical System Co., Ltd., Tomorrow Medical System Co., Ltd., and Hsing-Yeh Biotechnology Co., Ltd. and the control over those companies' operations.

If the Company fails to meet abovementioned requirement, First Commercial Bank will determine whether there has been a breach of contract and, if necessary, call a meeting with all the syndicate lenders to discuss the matter.

C. Information on assets pledged as collateral for long-term borrowings is provided in Note 8.

(18) Pensions

- A. Effective July 1, 2005, the Company and its domestic subsidiaries have established a defined contribution pension plan (the "New Plan") under the Labor Pension Act (the "Act"), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company and its domestic subsidiaries contribute monthly an amount based on 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment. The pension costs under the defined contribution pension plans of the Group for the years ended December 31, 2023 and 2022 were \$10,163 and \$9,017 respectively.
- B. The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. The pension plan is administered by the government. Other than the monthly contributions, the Group has no further obligations. The pension costs under the defined contribution pension plans of the Group for the years ended December 31, 2023 and 2022 were \$1,387 and \$1,310, respectively.

(19) Share-based payment

- A. As of December 31, 2023 and 2022, the Company's share-based payment transactions are as follows:

<u>Type of arrangement</u>	<u>Grant date</u>	<u>Quantity Granted (in thousands of shares)</u>	<u>Contract period</u>	<u>Vesting conditions</u>
Employee stock options-106	2018.4.13	2,000	7 years	Note

Note: After two years from the grant date, employees are allowed to exercise their stock options according to the vesting schedule specified in the plan.

B. Details of the share-based payment arrangements are as follows:

Stock options	2023		2022	
	No. of options (in thousands of shares)	Weighted-average exercise price (in dollars)	No. of options (in thousands of shares)	Weighted-average exercise price (in dollars)
Options outstanding at January 1	855	\$ 27.40	1,358	\$ 28.80
Options forfeited	(10)	26.50	(4)	27.40
Options exercised	(673)	27.29	(499)	28.75
Options outstanding at December 31	<u>172</u>	26.50	<u>855</u>	27.40
Options exercisable at December 31	<u>172</u>		<u>385</u>	

C. For the years ended December 31, 2023 and 2022, the weighted-average stock price of stock options on exercise dates were NT\$66.42 and NT\$46.90 (in dollars), respectively.

D. The expiry date and exercise price of stock options outstanding at the balance sheet date are as follows:

Issue date approved	Expiry date	December 31, 2023		December 31, 2022	
		No. of shares (in thousands of shares)	Exercise price (in dollars)	No. of shares (in thousands of shares)	Exercise price (in dollars)
2018.4.13	2025.4.12	172	\$ 26.50	855	\$ 27.40

E. The Black-Scholes option pricing model was used for valuation of fair value of the stock options granted. The related information is listed as follows:

Type of arrangement	Grant date	Stock price (in dollars)	Exercise price (in dollars)	Expected price volatility	Expected option life	Expected dividends	Risk-free interest rate fair value	Fair value per unit (in dollars)
Employee stock options-106	2018.4.13	\$ 34.50	\$ 34.50	30.02%	5.25 years	0%	0.75%	\$8.46~ \$10.91

F. Expenses incurred on the Group's share-based payment transactions are shown below:

	Years ended December 31,	
	2023	2022
Equity-settled	<u>\$ 286</u>	<u>\$ 1,758</u>

G. On July 18, 2023, July 19, 2022, November 29, 2021 and August 3, 2021, the exercise prices of employee stock options-106 were adjusted to NT\$26.5, NT\$27.4, NT\$28.8 and NT\$28.8 (in dollars), respectively, according to the rules of the employee stock option plan.

(20) Share capital

A. As of December 31, 2023, the Company's authorised capital was \$2,500,000, consisting of 250 million shares of ordinary stock, and the paid-in capital was \$1,664,194 with a par value of \$10 (in dollars) per share. All proceeds from shares issued have been collected. The aforementioned paid-in capital included 673 thousand shares of employee share options exercised and 4,193 thousand shares of convertible bonds converted for the year ended

December 31, 2023. The Company has applied to the regulatory authority for registration of the changes in capital on January 10, 2024, and the registration was completed on February 5, 2024.

Movements in the number of the Company's ordinary shares outstanding are as follows:

	(In thousands of shares)	
	2023	2022
At January 1	161,553	161,054
Employee stock options exercised	673	499
Conversion of convertible bonds	4,193	-
At December 31	166,419	161,553

- B. To attract strategic investors, strengthen the Company's financial structure, enrich working capital and improve the benefits of future competitiveness, the stockholders at their annual stockholders' meeting on July 1, 2021 adopted a resolution to raise additional cash through private placement. The maximum number of shares to be issued through the private placement is 20,000 thousand shares. The capital increase shall be processed in installments (no more than three times) within one year from the date of the resolution of the stockholders' meeting. The stockholders authorised the Board of Directors to determine the actual pricing date and issuance price within the range of not less than the percentage of the resolution of the stockholders' meeting considering the situation of the specific person and the market in the future. As resolved by the Board of Directors on October 6, 2021, the first effective date was on October 13, 2021, and the number of shares issued was 4,722 thousand shares at the subscription price of \$35.1 (in dollars) per share. The amount of capital raised through the private placement was \$165,742 which had been registered. Pursuant to the Securities and Exchange Act, the ordinary shares raised through the private placement are subject to certain transfer restrictions and cannot be listed on the stock exchange until three years after they have been issued and have been offered publicly. Other than these restrictions, the rights and obligations of the ordinary shares raised through the private placement are the same as other issued ordinary shares.

(21) Capital surplus

- A. Pursuant to Paragraph 4, Article 31 of the Business Mergers and Acquisitions Act, if a company becomes a wholly-owned subsidiary of another company through a share exchange, its undistributed earnings become part of the capital surplus of the acquiring company (parent company). Therefore, if the increase in the investment holding company's capital surplus is from the undistributed earnings of the subsidiary before the share exchange, this amount can be distributed as cash dividends or capitalised. Moreover, the proportion that can be capitalised is not subject to the restrictions set forth in Article 8 of the Securities and Exchange Act Enforcement Rules. In addition, according to Tai-Cai-Rong-Yi-Zi No. 0910016280, such increase in capital surplus was not generated by the holding company's business operations and thus will not affect the remuneration of directors and supervisors

and bonuses of employees. As of December 31, 2023, capital surplus that is attributable to the undistributed earnings of Chiu Ho Medical System Co., Ltd. and other associates before share exchanges amounted to \$44,390.

- B. Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. However, capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.
- C. Please refer to Note 6(19) for information on capital surplus - employee stock options.

(22) Retained earnings

- A. Under the Company's Articles of Incorporation, the current year's earnings, if any, shall first be used to pay all taxes and offset prior years' operating losses and then 10% of the remaining amount shall be set aside as legal reserve unless legal reserve equals the authorised share capital. Special reserve is then appropriated or reversed in accordance with related regulations. At least 50% of the remainder, if any, and accumulated undistributed earnings from prior years shall be proposed by the Board of Directors for appropriation. The proposal for the appropriation of earnings shall be approved by the shareholders if dividends are distributed by issuing new shares and shall be reported to the shareholders during their meeting after being specially resolved by the Board of Directors if dividends are distributed in the form of cash.
- B. Except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in capital.
- C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.
- D. The appropriations of 2022 and 2021 earnings which were resolved at the shareholders' meeting on June 12, 2023 and June 15, 2022, respectively, are as follows:

	Years ended December 31,			
	2022		2021	
	Amount	Dividends per share (in dollars)	Amount	Dividends per share (in dollars)
Legal reserve	\$ 35,657		\$ 38,163	
Special reserve	-		8,584	
Reversal of special reserve (	8,284)		-	
Cash dividends	<u>324,722</u>	\$ 2.01	<u>323,879</u>	\$ 2.01
	<u>\$ 352,095</u>		<u>\$ 370,626</u>	

The aforementioned earnings appropriations for the years ended December 31, 2022 and 2021 were in agreement with the amounts resolved by the Board of Directors during its meetings held on March 22, 2023 and March 23, 2022, respectively, and the ex-dividend dates resolved in the same meetings were July 18, 2023 and July 19, 2022, respectively. For more information on the aforementioned earnings appropriations proposed by the Board of Directors and resolved by the shareholders, please go to the Market Observation Post System website maintained by the Taiwan Stock Exchange.

- E. The appropriations for 2023 earnings as resolved by the Board of Directors on March 13, 2024 are as follows:

	Year ended December 31, 2023	
	Amount	Dividends per share (in dollars)
Legal reserve	\$ 41,887	
Reversal of special reserve	(1,760)	
Cash dividends	<u>334,503</u>	\$ 2.01
	<u>\$ 374,630</u>	

(23) Operating revenue

	Years ended December 31,	
	2023	2022
Revenue from contracts with customers	\$ 2,693,987	\$ 1,834,467
Rental revenue	1,174,358	1,131,888
Others	<u>8,792</u>	<u>7,997</u>
	<u>\$ 3,877,137</u>	<u>\$ 2,974,352</u>

- A. Disaggregation of revenue from contracts with customers

The Group's revenue is derived from the transfer of goods and services over time and at a point in time in the following major product lines:

Year ended December 31, 2023	Sale of medical instruments and drugs	Repairs and maintenance and other services	Others	Total
Revenue from external customer contracts	<u>\$ 2,346,677</u>	<u>\$ 313,368</u>	<u>\$ 33,942</u>	<u>\$2,693,987</u>
Timing of revenue recognition				
At a point in time	\$ 2,346,677	\$ 928	\$ 33,942	\$2,381,547
Over time	<u>-</u>	<u>312,440</u>	<u>-</u>	<u>312,440</u>
	<u>\$ 2,346,677</u>	<u>\$ 313,368</u>	<u>\$ 33,942</u>	<u>\$2,693,987</u>

Year ended December 31, 2022	Sale of medical instruments and drugs	Repairs and maintenance and other services	Others	Total
Revenue from external customer contracts	<u>\$ 1,528,184</u>	<u>\$ 273,533</u>	<u>\$ 32,750</u>	<u>\$1,834,467</u>
Timing of revenue recognition				
At a point in time	\$ 1,528,184	\$ 243	\$ 32,750	\$1,561,177
Over time	<u>-</u>	<u>273,290</u>	<u>-</u>	<u>273,290</u>
	<u>\$ 1,528,184</u>	<u>\$ 273,533</u>	<u>\$ 32,750</u>	<u>\$1,834,467</u>

B. Contract assets and liabilities

- (a) The Group recognised contract assets and liabilities in relation to contract revenue arising from sales, maintenance and repairs of medical instruments and other services as follows:

	December 31, 2023	December 31, 2022	January 1, 2022
Contract assets	<u>\$ 111,109</u>	<u>\$ 106,751</u>	<u>\$ 103,866</u>
Contract liabilities	<u>\$ 760,294</u>	<u>\$ 699,107</u>	<u>\$ 681,141</u>

- (b) Revenue recognised that was included in the contract liability balance at the beginning of the year

	Years ended December 31,	
	2023	2022
Revenue recognised that was included in the contract liability balance at the beginning of the year	<u>\$ 47,440</u>	<u>\$ 34,886</u>

C. Unfulfilled long-term repairs, maintenance and medical instrument contracts

Aggregate amount of the transaction price allocated to long-term contracts that are partially or fully unsatisfied as at December 31, 2023 and 2022, amounted to \$1,484,124 and \$1,415,163, respectively.

Management expects that the transaction price allocated to the unsatisfied contracts as of December 31, 2023 and 2022 will be recognised as revenue from 2023 to 2032.

Except for the abovementioned contracts, all other repairs and maintenance contracts are for

periods of one year or less or are billed based on time incurred. As permitted under IFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

(24) Interest income

	Years ended December 31,	
	2023	2022
Interest income from bank deposits	\$ 8,925	\$ 2,109
Interest income from financial assets measured at amortised cost	5,284	3,447
Finance income from sublease of right-of-use assets	6,310	3,959
Other interest income	164	3,015
	<u>\$ 20,683</u>	<u>\$ 12,530</u>

(25) Other income

	Years ended December 31,	
	2023	2022
Rent income	\$ 141	\$ 2,632
Dividend income	1,565	3,508
Government grant income	856	-
Other income	5,327	6,904
	<u>\$ 7,889</u>	<u>\$ 13,044</u>

(26) Other gains and losses

	Years ended December 31,	
	2023	2022
Losses on disposal of property, plant and equipment	(\$ 1,331)	(\$ 50,780)
Gains on disposal of investment property	-	106,590
Gains arising from lease modifications	162	-
Net currency exchange (losses) gains	(5,337)	19,689
Net gains (losses) on financial assets and liabilities at fair value through profit or loss	13,089	(17,992)
Other losses	(1,804)	(3,405)
	<u>\$ 4,779</u>	<u>\$ 54,102</u>

(27) Finance costs

	Years ended December 31,	
	2023	2022
Interest expense:		
Bank borrowings	\$ 51,131	\$ 35,985
Convertible bonds	9,874	10,646
Long-term contract liabilities	12,534	9,774
Lease liability	3,801	2,487
Financial expense, others	11,661	12,375
	<u>\$ 89,001</u>	<u>\$ 71,267</u>

(28) Expenses by nature

	Years ended December 31,	
	2023	2022
Employee benefit expense		
Wages and salaries	\$ 295,457	\$ 288,592
Employee stock options	286	1,758
Labour and health insurance fees	22,807	20,223
Pension costs	11,550	10,327
Other personnel expenses	11,048	8,562
Depreciation charge	572,563	478,142
Amortisation charge	21,900	21,240
	<u>\$ 935,611</u>	<u>\$ 828,844</u>

- A. In accordance with the Articles of Incorporation of the Company, a ratio of distributable profit of the current year (i.e. profit before tax less profit margin before the appropriation of employees' compensation and directors' remuneration), after covering accumulated losses, shall be distributed as employees' compensation and directors' remuneration. The ratio shall not be lower than 0.05% for employees' compensation and shall not be higher than 5% for directors' and supervisors' remuneration.

The aforementioned employees' compensation and directors' remuneration requires the approval from the majority of the directors attending a board meeting, with more than two thirds of all directors in attendance, and must be reported to the shareholders.

Employees' compensation is distributed in the form of shares or cash, and the recipients may include employees of affiliates who meet certain conditions. The distribution plan is set by the Chairman.

- B. For the years ended December 31, 2023 and 2022, employees' compensation was accrued at \$230 and \$190, respectively; directors' remuneration was both accrued at \$5,600. The aforementioned amounts were recognised in salary expenses.

Employees' compensation of \$190 and directors' remuneration of \$5,600 for 2022 as resolved by the Board of Directors were in agreement with those amounts recognised in the 2022 financial statements.

Information about employees' compensation and directors' remuneration of the Company as resolved at the meeting of the Board of Directors and approved by the shareholders at their meeting will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(29) Income tax

A. Income tax expense

(a) Components of income tax expense:

	Years ended December 31,	
	2023	2022
Current tax:		
Current tax on profits for the year	\$ 141,972	\$ 95,187
Tax on undistributed surplus earnings	226	383
Prior year income tax underestimation	688	1,512
Total current tax	142,886	97,082
Deferred tax		
Origination and reversal of temporary differences	(8,694)	(1,897)
Income tax expense	<u>\$ 134,192</u>	<u>\$ 95,185</u>

(b) Reconciliation between income tax expense and accounting profit:

	Years ended December 31,	
	2023	2022
Income tax calculated based on profit before tax and statutory tax rate	\$ 211,781	\$ 187,797
Expenses disallowed by tax regulation	-	6,958
Tax exempt income by tax regulation	(97,524)	(125,431)
Temporary differences not recognised as deferred tax assets	4,561	3,620
Taxable loss not recognised as deferred tax assets	756	19,646
Change in assessment of realisation of deferred tax assets	13,473	700
Prior year income tax underestimation	688	1,512
Effect from Alternative Minimum Tax	231	-
Tax on undistributed surplus earnings	226	383
Income tax expense	<u>\$ 134,192</u>	<u>\$ 95,185</u>

(c) The income tax (charge)/credit relating to components of other comprehensive income is as follows:

	Years ended December 31,	
	2023	2022
Currency translation differences	<u>(\$ 7)</u>	<u>(\$ 2)</u>

B. Amounts of deferred tax assets or liabilities as a result of temporary differences and tax losses are as follows:

	2023				
	<u>January 1</u>	<u>Recognised in profit or loss</u>	<u>Recognised in other comprehensive income</u>	<u>Business combination</u>	<u>December 31</u>
Temporary differences					
- Deferred tax assets:					
Unrealised allowance for inventory obsolescence	\$ 13,127	\$ 2,137	\$ -	\$ -	\$ 15,264
Unrealised exchange loss	1,137	(674)	-	-	463
Warranty obligations	2,925	(200)	-	-	2,725
Long-term contract liabilities interest expense	8,857	2,507	-	-	11,364
Others	3,867	(496)	-	-	3,371
Income tax losses	<u>58,817</u>	<u>1,236</u>	<u>-</u>	<u>-</u>	<u>60,053</u>
	<u>88,730</u>	<u>4,510</u>	<u>-</u>	<u>-</u>	<u>93,240</u>
Temporary differences					
- Deferred tax liabilities:					
Land revaluation increment tax	(39,395)	-	-	(10,507)	(49,902)
Book-tax difference on intangible assets from business combinations	(49,635)	4,256	-	(1,087)	(46,466)
Others	(2,785)	(72)	(7)	-	(2,864)
	<u>(91,815)</u>	<u>4,184</u>	<u>(7)</u>	<u>(11,594)</u>	<u>(99,232)</u>
	<u>(\$ 3,085)</u>	<u>\$ 8,694</u>	<u>(\$ 7)</u>	<u>(\$ 11,594)</u>	<u>(\$ 5,992)</u>

	2022				
	<u>January 1</u>	<u>Recognised in profit or loss</u>	<u>Recognised in other comprehensive income</u>	<u>Business combination</u>	<u>December 31</u>
Temporary differences					
- Deferred tax assets:					
Unrealised allowance for inventory obsolescence	\$ 11,589	\$ 1,538	\$ -	\$ -	\$ 13,127
Unrealised exchange loss	4,464	(3,327)	-	-	1,137
Warranty obligations	3,488	(563)	-	-	2,925
Long-term contract liabilities interest expense	6,902	1,955	-	-	8,857
Others	3,565	302	-	-	3,867
Income tax losses	<u>59,182</u>	<u>(365)</u>	<u>-</u>	<u>-</u>	<u>58,817</u>
	<u>89,190</u>	<u>(460)</u>	<u>-</u>	<u>-</u>	<u>88,730</u>
Temporary differences					
- Deferred tax liabilities:					
Land revaluation increment tax	(39,395)	-	-	-	(39,395)
Book-tax difference on intangible assets from business combinations	(53,859)	4,224	-	-	(49,635)
Others	<u>(916)</u>	<u>(1,867)</u>	<u>(2)</u>	<u>-</u>	<u>(2,785)</u>
	<u>(94,170)</u>	<u>2,357</u>	<u>(2)</u>	<u>-</u>	<u>(91,815)</u>
	<u>(\$ 4,980)</u>	<u>\$ 1,897</u>	<u>(\$ 2)</u>	<u>\$ -</u>	<u>(\$ 3,085)</u>

C. Expiration dates of unused tax losses and amounts of unrecognised deferred tax assets are as follows:

December 31, 2023					
<u>Year incurred</u>	<u>Amount filed/assessed</u>	<u>Unused amount</u>	<u>Unrecognised deferred tax assets</u>	<u>Expiry year</u>	
2013	\$ 17,125	\$ -	\$ -	2023	
2014	4,626	347	347	2024	
2015	9,659	2,798	2,798	2025	
2016	10,904	3,359	3,359	2026	
2017	15,829	888	888	2027	
2018	311,804	295,411	1	2028	
2019	3,262	2,528	2,528	2029	
2020	4,842	4,842	4,842	2030	
2021	7,036	7,036	7,036	2031	
2022	15,706	15,706	14,030	2032	
2023	<u>72,690</u>	<u>72,690</u>	<u>66,512</u>	2033	
	<u>\$ 473,483</u>	<u>\$ 402,605</u>	<u>\$ 102,341</u>		

December 31, 2022

<u>Year incurred</u>	<u>Amount filed/assessed</u>	<u>Unused amount</u>	<u>Unrecognised deferred tax assets</u>	<u>Expiry year</u>
2012	\$ 5,451	\$ -	\$ -	2022
2013	17,125	-	-	2023
2014	4,626	347	347	2024
2015	9,659	2,798	2,798	2025
2016	10,904	3,359	3,359	2026
2017	15,829	888	888	2027
2018	311,804	292,411	1	2028
2019	3,262	2,528	2,528	2029
2020	4,842	4,842	4,842	2030
2021	7,036	7,036	7,036	2031
2022	15,125	15,125	13,449	2032
	<u>\$ 405,663</u>	<u>\$ 329,334</u>	<u>\$ 35,248</u>	

- D. The amounts of deductible temporary differences that were not recognised as deferred tax assets are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Deductible temporary differences	<u>\$ 148,226</u>	<u>\$ 118,922</u>

- E. Income tax assessment of the Company and its domestic subsidiaries is as follows:

	<u>Recent assessment</u>
The Company, SenCare Healthcare Company, Hsing-Yeh Biotechnology Co., Ltd., Chiu Ho Biotech Co., Ltd., Shin-Ho Instruments Co., Ltd., E Century Healthcare Corporation, Hua Lin Instruments Co., Ltd., Tong-Lin Instruments Co., Ltd., Treasure of Health Co., Ltd., CHC Long-Term Care Corporation, Tomorrow Medical System Co., Ltd., Chiu Ho Scientific Co., Ltd., Hsin Lin Biotech Co., Ltd., Chiu Ho Medical System Co., Ltd., Xing-An Long-Term Care Corporation	Through 2021

(30) Earnings per share

Year ended December 31, 2023			
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
<u>Basic earnings per share</u>			
Profit attributable to ordinary shareholders of the parent	\$ 418,866	164,454	\$ 2.55
<u>Diluted earnings per share</u>			
Profit attributable to ordinary shareholders of the parent	\$ 418,866	164,454	
Assumed conversion of all dilutive potential ordinary shares			
Employee stock options	-	225	
Employees' compensation	-	4	
Convertible bonds	18,639	28,888	
Profit attributable to ordinary shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 437,505	193,571	\$ 2.26
Year ended December 31, 2022			
	Amount after tax	Weighted average number of ordinary shares outstanding (shares in thousands)	Earnings per share (in dollars)
<u>Basic earnings per share</u>			
Profit attributable to ordinary shareholders of the parent	\$ 356,571	161,381	\$ 2.21
<u>Diluted earnings per share</u>			
Profit attributable to ordinary shareholders of the parent	\$ 356,571	161,381	
Assumed conversion of all dilutive potential ordinary shares			
Employee stock options	-	314	
Employees' compensation	-	5	
Convertible bonds	22,716	30,112	
Profit attributable to ordinary shareholders of the parent plus assumed conversion of all dilutive potential ordinary shares	\$ 379,287	191,812	\$ 1.98

Because employees' compensation may be distributed in the form of shares, the calculation of diluted earnings per share assumes that employees' compensation would be distributed entirely in shares. These dilutive potential common shares are included in the weighted average number of outstanding shares when calculating diluted earnings per share. When calculating basic earnings per share, shares issued as part of employees' compensation are included in the weighted average number of outstanding shares only if the number of such shares have been confirmed and resolved by the Board of Directors. Shares issued as part of employees' compensation are not considered bonus shares, therefore no retrospective adjustment is applied when calculating basic and diluted earnings per share.

(31) Business combinations

- A. On January 1, 2023, the Company's indirect subsidiary, SenCare, acquired 51% of the share capital of Cin-An and 50.7% of the capital contribution of Xing-An LTC for \$54,361 and \$8,659, respectively, and obtained control over Cin-An and Xing-An LTC, operating elderly residence and providing long-term care service in the Republic of China, respectively. As a result of the acquisition, the Company is expected to expand its business and operating scale.
- B. The following table summarises the consideration paid for Cin-An and Xing-An LTC and the fair values of the assets acquired and liabilities assumed at the acquisition date, as well as the non-controlling interest's proportionate share of the recognised amounts of acquiree's identifiable net assets at the acquisition date:

<u>Cin-An</u>	<u>January 1, 2023</u>
Purchase consideration	
Cash paid	\$ 54,361
Non-controlling interest's proportionate share of the recognised amounts of acquiree's identifiable net assets	<u>38,469</u>
	<u>92,830</u>
Fair value of the identifiable assets acquired and liabilities assumed	
Cash and bank deposits	100
Invested properties	106,233
Long-term borrowings	(16,388)
Deferred income tax liabilities	(11,437)
Total identifiable net assets	<u>78,508</u>
Goodwill	<u>\$ 14,322</u>

<u>Xing-An LTC</u>	<u>January 1, 2023</u>
Purchase consideration	
Cash paid	\$ 8,659
Non-controlling interest's proportionate share of the recognised amounts of acquiree's identifiable net assets	<u>6,916</u>
	<u>15,575</u>
Fair value of the identifiable assets acquired and liabilities assumed	
Cash and bank deposits	13,400
Customer relationship	785
Deferred income tax liabilities	(<u>157</u>)
Total identifiable net assets	<u>14,028</u>
Goodwill	<u>\$ 1,547</u>

(32) Supplemental cash flow information

Information on investing activities with partial cash payments is provided in Notes 6(9) and (12).

(33) Changes in liabilities from financing activities

	<u>Short-term borrowings</u>	<u>Bonds payable</u>	<u>Long-term borrowings</u>	<u>Lease liability</u>	<u>Guarantee deposits received</u>	<u>Total liabilities from financing activities</u>
January 1, 2023	\$ 339,545	\$1,510,024	\$ 3,007,150	\$ 185,091	\$ 10,382	\$ 5,052,192
Changes in cash flow from financing activities	46,355	-	244,087	(33,510)	3,453	260,385
Changes in acquisition of subsidiaries	-	-	16,388	-	-	16,388
Impact of changes in foreign exchange rate	-	-	(292)	-	(71)	(363)
Changes in other non-cash items	(<u>26,825</u>)	(<u>192,958</u>)	<u>34,438</u>	<u>89,641</u>	<u>-</u>	(<u>95,704</u>)
December 31, 2023	<u>\$ 359,075</u>	<u>\$1,317,066</u>	<u>\$ 3,301,771</u>	<u>\$ 241,222</u>	<u>\$ 13,764</u>	<u>\$ 5,232,898</u>

	<u>Short-term borrowings</u>	<u>Bonds payable</u>	<u>Long-term borrowings</u>	<u>Lease liability</u>	<u>Guarantee deposits received</u>	<u>Total liabilities from financing activities</u>
January 1, 2022	\$ 636,211	\$1,499,378	\$ 2,715,606	\$ 126,959	\$ 13,561	\$ 4,991,715
Changes in cash flow from financing activities	(296,666)	-	286,700	(23,737)	(3,231)	(36,934)
Impact of changes in foreign exchange rate	-	-	326	-	52	378
Changes in other non-cash items	<u>-</u>	<u>10,646</u>	<u>4,518</u>	<u>81,869</u>	<u>-</u>	<u>97,033</u>
December 31, 2022	<u>\$ 339,545</u>	<u>\$1,510,024</u>	<u>\$ 3,007,150</u>	<u>\$ 185,091</u>	<u>\$ 10,382</u>	<u>\$ 5,052,192</u>

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The Company's stocks are held by the public, so it has neither an ultimate parent company nor ultimate controlling party.

(2) Names of related parties and relationship

<u>Names of related parties</u>	<u>Relationship with the Group</u>
Yeezen General Hospital	Substantive related party
High-END VISION EYE CENTER	Substantive related party
Swissray Medical AG	Substantive related party
Shin Shin Healthcare Co., Ltd.	Substantive related party
SWISSRAY ASIA HEALTHCARE COMPANY LIMITED	Substantive related party
SOAR MEDICAL TECH CO., LTD.	Substantive related party
AESolution Biomedical Co., Ltd.	Substantive related party
J. Ab Beauty Co., Ltd.	Substantive related party
Chen Lin Charity Foundation	Substantive related party
Treasure of Health Pharmacy (Nangang)	Substantive related party
Treasure of Health Pharmacy (Donghu)	Substantive related party
Kun-Zhang Su	Substantive related party
Yu-Zhi Zhuang	Substantive related party
Yu-Hsiu Wang	Substantive related party
Errand Co., Ltd.	Substantive related party
EARK Exotic Animal Hospital (Note)	Substantive related party
CHENG-HSIN Biotechnology Co., Ltd.	Associate
Note: It was named ARK Exotic Animal Hospital and changed to EARK Exotic Animal Hospital on September 1, 2023.	

(3) Significant transactions and balances with related parties

A. Operating revenue

(a) Sales revenue

	<u>Years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Sales of goods:		
Yeezen General Hospital	\$ 174,913	\$ 162,451
Substantive related party	108,099	120,101
Associate	286	501
	<u>\$ 283,298</u>	<u>\$ 283,053</u>

In terms of the transactions between the subsidiaries, Chiu Ho Scientific Co., Ltd. and Treasure of Health Co., Ltd., and the abovementioned related parties, goods are sold based on the price lists in force and terms that would be available to third parties. Hsing-Yeh Biotechnology Co., Ltd., Chiu Ho Medical System Co., Ltd. and Exotic Pet Care Experts Co., Ltd. and the abovementioned related parties have no other similar transactions that can be used for comparison. The collection period is approximately

2~6 months.

(b) Rental revenue

	Years ended December 31,	
	2023	2022
Rental revenue:		
Substantive related party	\$ 100,708	\$ 94,160

- i. The subsidiaries, Hsing-Yeh Biotechnology Co., Ltd. and Chiu Ho Medical System Co., Ltd., lease property to the abovementioned related parties. The lease terms are from 2020 to 2028. Lease payments are determined by negotiations between the two parties and are made monthly.
- ii. The subsidiaries, Chiu Ho Scientific Co., Ltd., E Century Healthcare Corporation and Chiu Ho Medical System Co., Ltd. and Exotic Pet Care Experts Co., Ltd., lease medical equipment to the abovementioned related parties. The lease terms are from 2016 to 2031. The monthly lease payment is set as a predetermined percentage of the monthly revenue of the related party. The collection period is between 2 and 6 months.

(c) Royalty income

	Years ended December 31,	
	2023	2022
Royalty income:		
Substantive related party	\$ 4,602	\$ 5,063

Royalty income was collected because the subsidiary, Treasure of Health Co., Ltd., provided trademark licenses to the abovementioned related parties. The licensing fee received in each period is calculated according to the agreed percentage of the abovementioned related parties' monthly sales revenue. The collection term was 2 months.

B. Purchases

	Years ended December 31,	
	2023	2022
Purchases of goods:		
Substantive related party	\$ 8,017	\$ 4,823
Purchases of services:		
Substantive related party	1,730	657
	\$ 9,747	\$ 5,480

The subsidiaries, Chiu Ho Scientific Co., Ltd., Chiu Ho Medical System Co., Ltd., and Treasure of Health Co., Ltd. and Sen Care Healthcare Company and the abovementioned related parties have no other similar transactions that can be used for comparison. In terms of the transactions between Treasure of Health Co., Ltd and the abovementioned related parties, goods are purchased based on the price lists in force and terms that would be

available to third parties. The payment period is between 1 and 3 months.

C. Donation expense (shown as ‘operating expenses’)

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Chen Lin Charity Foundation	\$ 1,000	\$ 1,000

The subsidiary, Chiu-Ho Medical System Co., Ltd., donated to Chen Lin Charity Foundation.

D. Notes and accounts receivable

(a) Receivables from related parties:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Yeezen General Hospital	\$ 202,704	\$ 195,283
Substantive related party	36,116	30,622
	<u>238,820</u>	<u>225,905</u>
Less: Allowance for doubtful accounts	-	-
	<u>\$ 238,820</u>	<u>\$ 225,905</u>

(b) Installment accounts receivable (shown as ‘accounts receivable - related parties’ and ‘long-term notes and accounts receivable - related parties’)

The subsidiary, Chiu Ho Medical System Co., Ltd., sold equipment to the related parties under installment payment and recognised installment receivables with maturity over a year as long-term installment receivables (shown as ‘long-term notes and accounts receivable - related parties’).

Reconciliation of the undiscounted total installment accounts receivable and the net installment accounts receivable of the equipment sold under installment payment on December 31, 2023 and 2022 is provided as follows:

There is no such reconciliation as of December 31, 2023.

	<u>December 31, 2022</u>		
	<u>Total installment accounts receivable</u>	<u>Unrealised interest income</u>	<u>Net installment accounts receivable</u>
<u>Current</u>			
Substantive related parties	\$ 1,076	(\$ 8)	\$ 1,068
Loss allowance	-	-	-
	<u>\$ 1,076</u>	<u>(\$ 8)</u>	<u>\$ 1,068</u>

(c) As of December 31, 2023, December 31, 2022 and January 1, 2022, the balances of receivables due from related parties from contracts with customers amounted to \$207,662, \$196,578, and \$179,165, respectively.

(d) Lease payments receivable (shown as ‘accounts receivable - related parties’ and long-term notes and accounts receivable - related parties)

The subsidiaries, Hsing-Yeh Biotechnology Co., Ltd., Chiu Ho Scientific Co., Ltd., and

E Century Healthcare Corporation, lease machinery and other equipment to Yeezen General Hospital under a finance lease. The lease terms are from 2017 to 2028. Based on the terms of the lease contract, the ownership of the equipment shall be transferred to the lessee when the lease expires. In addition, Hsing-Yeh Biotechnology Co., Ltd. leases renovation project assets to CHENG-HSIN Biotechnology Co., Ltd under a finance lease. The lease term is from 2017 to 2024 which is for the major part of economic life of the underlying asset. The lease payments from the aforementioned agreements are expected to be collected on schedule.

As of December 31, 2023 and 2022, reconciliation of the undiscounted lease payments and the net investment in the finance lease is provided as follows:

	December 31, 2023		
	Undiscounted lease payments	Unearned finance income	Net investment in the lease
<u>Current</u>			
Yeezen General Hospital	\$ 5,604	(\$ 322)	\$ 5,282
CHENG-HSIN Biotechnology Co., Ltd.	16,091	(70)	16,021
Loss allowance	-	-	-
	<u>\$ 21,695</u>	<u>(\$ 392)</u>	<u>\$ 21,303</u>
<u>Non-current</u>			
Yeezen General Hospital	\$ 8,558	(\$ 384)	\$ 8,174
Loss allowance	-	-	-
	<u>\$ 8,558</u>	<u>(\$ 384)</u>	<u>\$ 8,174</u>
	December 31, 2022		
	Undiscounted lease payments	Unearned finance income	Net investment in the lease
<u>Current</u>			
Yeezen General Hospital	\$ 6,335	(\$ 279)	\$ 6,056
CHENG-HSIN Biotechnology Co., Ltd.	20,672	(286)	20,386
Loss allowance	(1,564)	-	(1,564)
	<u>\$ 25,443</u>	<u>(\$ 565)</u>	<u>\$ 24,878</u>
<u>Non-current</u>			
Yeezen General Hospital	\$ 5,585	(\$ 170)	\$ 5,415
CHENG-HSIN Biotechnology Co., Ltd.	6,704	(70)	6,634
Loss allowance	-	-	-
	<u>\$ 12,289</u>	<u>(\$ 240)</u>	<u>\$ 12,049</u>

(e) The ageing analysis of accounts receivable due from related parties is as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Not past due	\$ 181,655	\$ 181,250
Past due		
Up to 1 month	20,713	24,392
Up to 2 months	19,496	14,239
Up to 3 months	17,740	16,716
Up to 4 months	11,301	11,119
Up to 5 months	17,392	15,402
Up to 6 months	-	782
Over 6 months	-	1,564
	<u>\$ 268,297</u>	<u>\$ 265,464</u>

The above receivables included the receivables generated from the Group's business activities of sales and lease of medical equipment and the ageing analysis was based on past due month.

(f) Information relating to credit risk is provided in Note 12(2).

E. Other receivables due from related parties

(a) Loans to related parties

<u>Year ended December 31, 2023</u>					
	<u>Maximum balance</u>	<u>Ending balance</u>	<u>Interest rate</u>	<u>Amount of interest</u>	<u>Ending balance of interest receivable</u>
Yeezen General Hospital	\$ 70,000	\$ -	2.5%	\$ 142	\$ -
High-END VISION EYE CENTER	1,000	-	2.5%	4	-
	<u>\$ 71,000</u>	<u>\$ -</u>		<u>\$ 146</u>	<u>\$ -</u>

<u>Year ended December 31, 2022</u>					
	<u>Maximum balance</u>	<u>Ending balance</u>	<u>Interest rate</u>	<u>Amount of interest</u>	<u>Ending balance of interest receivable</u>
Yeezen General Hospital	\$ 170,000	\$ 70,000	2.5%	\$ 2,939	\$ -
High-END VISION EYE CENTER	3,500	1,000	2.5%	70	-
	<u>\$ 173,500</u>	<u>\$ 71,000</u>		<u>\$ 3,009</u>	<u>\$ -</u>

(b) Proceeds from liquidation of investee transferred to other receivables

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Substantive related party	\$ <u>-</u>	\$ <u>369</u>

F. Accounts payable - related parties

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Substantive related party	\$ <u>1,873</u>	\$ <u>614</u>

The payables to related parties arise mainly from purchases and the payment term is 2~3 months. The payables bear no interest.

G. Property transactions

(a) Acquisition of property, plant and equipment

	<u>Year ended December 31, 2023</u>
Substantive related party	\$ <u>2,257</u>

There is no such transaction for the year ended December 31, 2022.

(b) Disposal of property, plant and equipment

	<u>Year ended December 31, 2023</u>	
	<u>Disposal proceeds</u>	<u>Gain (loss) on disposal</u>
Yeezen General Hospital	\$ <u>819</u>	\$ <u>31</u>

There is no such transaction for the year ended December 31, 2022.

H. Lease transactions - lessee

(a) The subsidiary, Treasure of Health Co., Ltd., leases offices and warehouses from Kun-Zhang Su and Errand Co.,Ltd. Rental contracts are made for periods of 10 years. Rents are paid at the beginning of the month.

(b) Acquisition of right-of-use assets

	<u>Year ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Kun-Zhang Su	\$ -	\$ 14,281
Errand Co., Ltd.	8,785	19,530
	\$ <u>8,785</u>	\$ <u>33,811</u>

(c) Lease liabilities

(i) Outstanding balance:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Kun-Zhang Su	\$ 11,830	\$ 13,525
Errand Co., Ltd.	25,411	18,496
	\$ <u>37,241</u>	\$ <u>32,021</u>

(ii) Interest expense

	Year ended December 31,	
	2023	2022
Kun-Zhang Su	\$ 222	\$ 119
Errand Co., Ltd.	447	163
	<u>\$ 669</u>	<u>\$ 282</u>

(4) Key management compensation

	Years ended December 31,	
	2023	2022
Salaries and other short-term employee benefits	\$ 43,877	\$ 41,942
Post-employment benefits	324	324
Share-based payments	32	190
	<u>\$ 44,233</u>	<u>\$ 42,456</u>

8. PLEDGED ASSETS

The Group's assets pledged as collateral are as follows:

Assets	Book value		Purpose
	December 31, 2023	December 31, 2022	
Financial assets at amortised cost - non-current			Performance and customs duty guarantee related to operations
-Time deposits	\$ 199,745	\$ 204,337	
Other non-current assets			
-Restricted bank deposits	4,736	11,060	Collateral for long-term borrowings
Property, plant and equipment (including investment property)			
-Land	895,491	808,838	Collateral for long-term borrowings
-Buildings and structures	1,063,817	442,251	Collateral for long-term borrowings
-Leased assets - machinery and equipment	247,597	293,787	Collateral for long-term borrowings
-Equipments pending acceptance	124,320	-	Collateral for long-term borrowings
	<u>2,331,225</u>	<u>1,544,876</u>	
	<u>\$ 2,535,706</u>	<u>\$ 1,760,273</u>	

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

(1) Contingencies

None.

(2) Commitments

A. Please refer to Note 6(17) for commitments related to the syndicated bank loan.

- B. As of December 31, 2023 and 2022, capital expenditures on property, plant and equipment and inventories contracted for but not yet incurred were \$500,444 and \$628,084, respectively.
- C. As of December 31, 2023 and 2022, amounts available under unused letters of credit were \$97,273 and \$415,255, respectively.
- D. As of December 31, 2023, privately offered funds investment quota contracted but not yet invested amounted to \$24,000. There was no such transaction as of December 31, 2022.

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Capital management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

(2) Financial instruments

A. Financial instruments by category

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
<u>Financial assets</u>		
Financial assets at fair value through profit or loss		
Financial assets mandatorily measured at fair value through profit or loss	<u>\$ 137,169</u>	<u>\$ 102,171</u>
Financial assets at fair value through other comprehensive income		
Designation of equity instruments	<u>\$ 36,959</u>	<u>\$ 29,578</u>

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Financial assets at amortised cost		
Cash and cash equivalents	\$ 1,891,381	\$ 1,472,849
Financial assets at amortised cost	265,834	409,481
Notes receivable	38,837	46,322
Accounts receivable (including related parties)	998,480	833,279
Other receivables (including related parties)	1,093	73,294
Other financial assets (shown as 'other non-current assets')	4,736	11,060
Long-term notes and accounts receivable (including related parties)	275,473	252,612
Guarantee deposits paid	319,068	265,118
	<u>\$ 3,794,902</u>	<u>\$ 3,364,015</u>
<u>Financial liabilities</u>		
Financial liabilities at amortised cost		
Short-term borrowings	\$ 359,075	\$ 339,545
Notes payable	21,216	20,993
Accounts payable	375,894	325,733
Other payables	194,966	121,185
Bonds payable	1,317,066	1,510,024
Long-term borrowings (including current portion and long-term deferred revenue)	3,269,479	2,980,293
Guarantee deposits received	13,764	10,382
	<u>\$ 5,551,460</u>	<u>\$ 5,308,155</u>
Lease liability	<u>\$ 241,222</u>	<u>\$ 185,091</u>

B. Financial risk management policies

- (a) The Group's operating activities expose it to a variety of financial risks, including market risk (including foreign exchange risk, interest rate risk and price risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial position and financial performance.
- (b) Risk management is carried out by a central treasury department (Group treasury) under policies approved by the Board of Directors. Group treasury identifies, evaluates and hedges financial risks in close cooperation with the Group's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as credit risk.

C. Significant financial risks and degrees of financial risks

(a) Market risk

Foreign exchange risk

- i. The Group conducts business worldwide and imports state-of-the-art medical equipment and supplies from various countries and is therefore exposed to foreign exchange risk from multiple foreign currencies, primarily the US dollar. Foreign exchange risk arises from future commercial transactions, recognised assets and liabilities and net investments in foreign operations.
- ii. Under the Group's financial risk management policy, foreign exchange risk is managed using debt denominated in the relevant foreign currency.
- iii. The Group's businesses involve some non-functional currency operations (the Company's and certain subsidiaries' functional currency: NTD; other certain subsidiaries' functional currency: RMB, HKD, IDR or GBP). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

	December 31, 2023			Year ended December 31, 2023	
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)	Sensitivity analysis	
				Extent of variation	Effect on profit or loss
(Foreign currency: functional currency)					
<u>Financial assets</u>					
<u>Monetary items</u>					
USD:NTD	\$ 8,830	30.71	\$ 271,169	1%	\$ 2,712
USD:HKD	1,324	7.81	40,660	1%	407
<u>Financial liabilities</u>					
<u>Monetary items</u>					
USD:NTD	5,631	30.71	172,928	1%	1,729
EUR:NTD	1,694	33.98	57,562	1%	576
SGD:NTD	622	23.29	14,486	1%	145

	December 31, 2022			Year ended December 31, 2022	
	Foreign currency amount (in thousands)	Exchange rate	Book value (NTD)	Sensitivity analysis	
				Extent of variation	Effect on profit or loss
(Foreign currency: functional currency)					
<u>Financial assets</u>					
<u>Monetary items</u>					
USD:NTD	\$ 7,859	30.71	\$ 241,350	1%	\$ 2,414
EUR:NTD	1,228	32.72	40,180	1%	402
USD:HKD	1,310	7.80	40,230	1%	402
<u>Financial liabilities</u>					
<u>Monetary items</u>					
USD:NTD	5,808	30.71	178,364	1%	1,784
EUR:NTD	990	32.72	32,393	1%	324
SGD:NTD	949	22.88	21,713	1%	217

- iv. The total exchange (loss) gain, including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Group for the years ended December 31, 2023 and 2022, amounted to (\$5,337) and \$19,689, respectively

Price risk

- i. The Group is exposed to equity price risk from its investments classified on the consolidated balance sheet either as financial assets measured at fair value through profit or loss and financial assets measured at fair value through other comprehensive income. The Group is not exposed to commodity price risk. To manage its price risk arising from investments in equity securities, the Group has set stop-loss points and therefore does not expect to incur significant losses from equity price risk.
- ii. The Group's investments in equity and debt securities comprise domestic and foreign listed and unlisted stocks. The prices of equity and debt securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 10% with all other variables held constant, post-tax profit for the years ended December 31, 2023 and 2022 would have increased/decreased by \$13,457 and \$10,187, respectively, as a result of gains/losses on equity and debt securities classified as at fair value through profit or loss. Other components of equity would have increased/decreased by \$3,696 and \$2,958, respectively, as a result of other comprehensive income classified as equity investment at fair value through other comprehensive income.

Cash flow and fair value interest rate risk

- i. The Group's interest rate risk arises from long-term borrowings. Long-term borrowings issued at variable rates expose the Group to cash flow interest rate risk, which is partially offset by cash and cash equivalents held at variable rates. The

Group's borrowings at variable rates are primarily denominated in NTD and USD.

- ii. If the borrowing interest rate had increased/decreased by 1% with all other variables held constant, profit, net of tax for the years ended December 31, 2023 and 2022 would have decreased/increased by \$32,896 and \$30,072, respectively. The main factor is that changes in interest expense result from floating rate borrowings.

(b) Credit risk

- i. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or financial instruments on the contract obligations. The main factor is the counterparties could not repay in full the accounts receivable based on the agreed terms, and the contract cash flows of debt instruments stated at amortised cost. According to the Group's credit policy, each local entity in the Group is responsible for managing and assessing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the credit control supervisor. The utilisation of credit limits is regularly monitored.
- ii. If the contract payments were past due over one month based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition; the default occurs when the contract payments are past due over three months and up to two years.
- iii. The following indicators are used to determine whether the credit impairment of debt instruments has occurred:
 - (i) It becomes probable that the issuer will enter bankruptcy or other financial reorganization due to their financial difficulties;
 - (ii) The disappearance of an active market for that financial asset because of financial difficulties;
 - (iii) Default or delinquency in interest or principal repayments;
 - (iv) Adverse changes in national or regional economic conditions that are expected to cause a default.
- iv. The Group classifies customer's accounts receivable and contract assets in accordance with customer types. The Group applies the modified approach using the provision matrix to estimate expected credit loss.
- v. The Group wrote-off the financial assets, which cannot be reasonably expected to be recovered, after initiating recourse procedures. However, the Group will continue executing the recourse procedures to secure their rights.
- vi. The Group took into consideration the forecastability to adjust historical and timely information to assess the default possibility of notes and accounts receivable (including long-term and related parties) and contract assets. On December 31, 2023 and 2022, the provision matrix is as follows:

<u>December 31, 2023</u>	<u>Expected loss rate</u>	<u>Total book value</u>	<u>Loss allowance</u>
Not past due	0.00%~1%	\$ 1,276,306	\$ 43
Up to 1 month	0.00%~2.59%	51,220	48
Up to 2 months	0.00%~31.48%	38,460	719
Up to 3 months	0.00%~43.08%	20,692	-
Up to 4 months	0.00%~100%	13,981	-
Up to 5 months	0.00%~100%	19,285	1,893
Up to 6 months	0.00%~100%	-	-
Over 6 months	30%~100%	10,487	3,829
		<u>\$ 1,430,431</u>	<u>\$ 6,532</u>

<u>December 31, 2022</u>	<u>Expected loss rate</u>	<u>Total book value</u>	<u>Loss allowance</u>
Not past due	0.00%~1.36%	\$ 1,130,070	\$ 173
Up to 1 month	0.00%~24.70%	42,254	64
Up to 2 months	0.00%~28.98%	18,165	189
Up to 3 months	0.00%~29.07%	20,628	165
Up to 4 months	0.00%~100%	12,036	655
Up to 5 months	0.00%~100%	16,314	650
Up to 6 months	0.00%~100%	1,316	349
Over 6 months	30%~100%	4,504	4,078
		<u>\$ 1,245,287</u>	<u>\$ 6,323</u>

vii. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable, contract assets, notes receivable, long-term and short-term lease payments receivable and other receivables are as follows:

	<u>2023</u>				
	<u>Accounts receivable (including related parties)</u>	<u>Contract assets (including related parties)</u>	<u>Notes receivable (including related parties)</u>	<u>Lease payments receivable (including related parties)</u>	<u>Other receivables (including related parties)</u>
At January 1	\$ 4,759	\$ -	\$ -	\$ 1,564	\$ 432
Provision for impairment	1,840	-	1	-	-
Reversal of impairment	-	-	-	(1,564)	-
Effect of foreign exchange	(68)	-	-	-	(8)
At December 31	<u>\$ 6,531</u>	<u>\$ -</u>	<u>\$ 1</u>	<u>\$ -</u>	<u>\$ 424</u>

	<u>2022</u>				
	<u>Accounts receivable (including related parties)</u>	<u>Contract assets (including related parties)</u>	<u>Notes receivable (including related parties)</u>	<u>Lease payments receivable (including related parties)</u>	<u>Other receivables (including related parties)</u>
At January 1	\$ 2,602	\$ -	\$ -	\$ -	\$ -
Provision for impairment	2,159	-	-	1,564	434
Effect of foreign exchange	(2)	-	-	-	(2)
At December 31	<u>\$ 4,759</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,564</u>	<u>\$ 432</u>

(c) Liquidity risk

- i. Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group treasury. Group treasury monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs. Such forecasting takes into consideration the Group's debt financing plans, covenant compliance, compliance with internal balance sheet ratio targets.
- ii. The table below analyses the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the expected or contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

Non-derivative financial liabilities:

December 31, 2023	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	Over 5 years
Short-term borrowings	\$ 364,488	\$ -	\$ -	\$ -
Notes payable	21,216	-	-	-
Accounts payable	375,894	-	-	-
Other payables	194,966	-	-	-
Lease liability	39,007	32,267	82,258	111,053
Bonds payable and embedded derivative instruments	-	1,331,902	-	-
Long-term borrowings (including current portion)	264,036	390,803	2,699,778	126,633

Non-derivative financial liabilities:

December 31, 2022	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	Over 5 years
Short-term borrowings	\$ 342,974	\$ -	\$ -	\$ -
Notes payable	20,993	-	-	-
Accounts payable	325,733	-	-	-
Other payables	121,185	-	-	-
Lease liability	30,292	27,503	58,062	85,735
Bonds payable and embedded derivative instruments	-	-	1,537,875	-
Long-term borrowings (including current portion)	115,473	196,195	2,721,069	185,331

(3) Fair value information

- A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value of the Group's investment in listed stocks is included in Level 1.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in equity and debt investment without active market is included in Level 3.

- B. Fair value information of investment property at cost is provided in Note 6(12).
- C. The carrying amount of a financial instrument not measured at fair value is a reasonable approximation of its fair value. Such financial instruments include cash and cash equivalents, financial assets at amortised cost, notes receivable, accounts receivable (including related parties), other receivables (including related parties), long-term notes and accounts receivable (including related parties), guarantee deposits paid, other financial assets, short-term borrowings, notes payable, accounts payable, other payables, long-term borrowings (including the current portion and long-term deferred revenue), bonds payable, guarantee deposits received and lease liability.
- D. The related information on financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

- (a) The related information on the nature of the assets and liabilities is as follows:

December 31, 2023	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Recurring fair value</u>				
<u>measurements</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ 69,380	\$ -	\$ -	\$ 69,380
Debt instruments	-	-	59,960	59,960
Derivative instruments	-	-	2,598	2,598
Privately offered funds	-	-	5,231	5,231
Financial assets at fair value through other comprehensive income				
Equity securities	10,159	-	26,800	36,959
	<u>\$ 79,539</u>	<u>\$ -</u>	<u>\$ 94,589</u>	<u>\$174,128</u>

December 31, 2022	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Recurring fair value</u>				
<u>measurements</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ 41,911	\$ -	\$ -	\$ 41,911
Debt instruments	-	-	59,960	59,960
Derivative instruments	-	-	300	300
Financial assets at fair value through other comprehensive income				
Equity securities	10,537	-	19,041	29,578
	<u>\$ 52,448</u>	<u>\$ -</u>	<u>\$ 79,301</u>	<u>\$131,749</u>

- (b) The methods and assumptions the Group used to measure fair value are as follows:
- Listed stocks are instruments whose fair values are measured using quoted market prices (that is, Level 1). The quoted market prices used for these stocks are the closing prices on the balance sheet date.
 - Except for financial instruments with active markets, the fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes.

E. For the years ended December 31, 2023 and 2022, there was no transfer between Level 1 and Level 2.

F. The following chart is the movement of Level 3 for the years ended December 31, 2023 and 2022.

	<u>2023</u>				
	<u>Equity securities</u>	<u>Privately offered funds</u>	<u>Debt instruments</u>	<u>Derivative financial instruments</u>	<u>Total</u>
At January 1	\$ 19,041	\$ -	\$ 59,960	\$ 300	\$ 79,301
Gains and losses recognised in profit or loss	-	(769)	-	2,886	2,117
Gains and losses recognised in other comprehensive income	7,759	-	-	-	7,759
Acquired during the year	-	6,000	-	-	6,000
Convertible bonds converted during the year	-	-	-	(588)	(588)
At December 31	<u>\$ 26,800</u>	<u>\$ 5,231</u>	<u>\$ 59,960</u>	<u>\$ 2,598</u>	<u>\$ 94,589</u>

	2022			
	Equity securities	Debt instruments	Derivative financial instruments	Total
At January 1	\$ 20,055	\$ 59,960	\$ -	\$ 80,015
Gains and losses recognised in profit or loss	-	-	300	300
Acquired during the year	-	-	-	-
Sold during the year	(1,014)	-	-	(1,014)
At December 31	<u>\$ 19,041</u>	<u>\$ 59,960</u>	<u>\$ 300</u>	<u>\$ 79,301</u>

- G. For the years ended December 31, 2023 and 2022, there was no transfer into or out from Level 3.
- H. Financial accounting department is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions and performing reviews regularly.
- I. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

	Fair value at December 31, 2023	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted stocks	\$ 26,800	Market comparable companies	Price to book ratio multiple	3.54 (3.54)	The higher the multiple, the higher the fair value
			Discount for lack of marketability	30.55% (30.55%)	The higher the discount for lack of marketability, the lower the fair value
Unlisted stocks	-	Net asset value	Not applicable	-	Not applicable
Privately offered funds	5,231	Net asset value	Not applicable	-	Not applicable
Non-derivative debt instrument:					
Unlisted stocks	59,960	Discounted cash flow method	Weighted average capital cost	14.64% (14.64%)	The higher the weighted average capital cost, the lower the fair value
Hybrid instrument:					
Convertible bonds	2,598	Binomial Model	Volatility	35.35% (35.35%)	The higher the volatility, the higher the fair value; The higher the discount rate, the lower the fair value
			Discount rate	1.4014% (1.4014%)	

	Fair value at December 31, 2022	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fair value
Non-derivative equity instrument:					
Unlisted stocks	\$ 19,041	Market comparable companies	Price to book ratio multiple Discount for lack of marketability	3.17 (3.17) 30.55% (30.55%)	The higher the multiple, the higher the fair value The higher the discount for lack of marketability, the lower the fair value
Unlisted stocks	-	Net asset value	Not applicable	-	Not applicable
Non-derivative debt instrument:					
Unlisted stocks	59,960	Discounted cash flow method	Weighted average capital cost	14.64% (14.64%)	The higher the weighted average capital cost, the lower the fair value
Derivative debt instrument:					
Convertible bonds	300	Binomial Model	Volatility Discount rate	29.20% (29.20%) 1.5415% (1.5415%)	The higher the volatility, the higher the fair value; The higher the discount rate, the lower the fair value

- J. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. For financial assets and financial liabilities classified as Level 3, an increase or decrease in their valuation parameter by 1% would have no material impact on gain or loss and other comprehensive income as at December 31, 2023 and 2022.

13. SUPPLEMENTARY DISCLOSURES

(1) Significant transactions information

(The following intercompany transactions between the Company and its subsidiaries or between two subsidiaries were eliminated when preparing the consolidated financial statements.)

- A. Loans to others: Refer to table 1.
- B. Provision of endorsements and guarantees to others: Refer to table 2.
- C. Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Refer to table 3.
- D. Acquisition or sale of the same security with the accumulated cost reaching \$300 million or 20% of paid-in capital or more: None.
- E. Acquisition of real estate reaching \$300 million or 20% of paid-in capital or more: Refer to table 4.
- F. Disposal of real estate reaching \$300 million or 20% of paid-in capital or more: None.

- G. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: Refer to table 5.
- H. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: Refer to table 6.
- I. Trading in derivative instruments undertaken during the reporting periods: None.
- J. Significant inter-company transactions during the reporting periods: None exceeds \$100 million.

(2) Information on investees

(The following intercompany transactions between the Company and its subsidiaries or between two subsidiaries were eliminated when preparing the consolidated financial statements.)

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 7.

(3) Information on investments in Mainland China

(The following intercompany transactions between the Company and its subsidiaries or between two subsidiaries were eliminated when preparing the consolidated financial statements.)

- A. Basic information: Refer to table 8.
- B. Limits on investments in Mainland China: Refer to table 8.
- C. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: There were no significant transactions.

(4) Major shareholders information

Refer to table 9.

14. SEGMENT INFORMATION

(1) General information

The Group operates business only in a single industry. The chief operating decision-maker, who allocates resources and assesses performance of the Group as a whole, has identified that the Group has only one reportable operating segment. The chief operating decision-maker assesses performance based on net profits, and the amounts of assets, liabilities, profits and losses provided to the decision-maker are consistent with those presented in the financial statements. Under one reportable segment, information on profits, losses, assets and liabilities of individual departments are not disclosed.

(2) Measurement of segment information

The chief operating decision-maker assesses performance based on net profits, and the amounts of assets, liabilities, profits and losses provided to the decision-maker are consistent with those presented in the financial statements. Under one reportable segment, information on profits, losses, assets and liabilities of individual departments are not disclosed.

(3) Information on products and services

Because the Company and its subsidiaries are all engaged in sales of drugs and sales, rent and installment and maintenance of medical devices, information on products and services is the same with the financial information provided in Note 6 (23).

(4) Geographical information

Geographical information for the years ended December 31, 2023 and 2022 is as follows:

	Years ended December 31,			
	2023		2022	
	<u>Revenue (Note)</u>	<u>Non-current assets</u>	<u>Revenue (Note)</u>	<u>Non-current assets</u>
Taiwan	\$ 3,825,256	\$ 8,045,912	\$ 2,869,079	\$ 7,848,916
China	43,817	229,083	94,867	210,250
Others	8,064	155	9,406	183
	<u>\$ 3,877,137</u>	<u>\$ 8,275,150</u>	<u>\$ 2,974,352</u>	<u>\$ 8,059,349</u>

Note: Revenue was reclassified based on the country where the customers are located.

(5) Major customer information

	Years ended December 31,	
	2023	2022
	<u>Revenue</u>	<u>Revenue</u>
Customer A	<u>\$ 261,541</u>	<u>\$ 247,899</u>

CHC Healthcare Group and Subsidiaries

Loans to others

For the year ended December 31, 2023

Table 1

Expressed in thousands of NTD
(Except as otherwise indicated)

No. (Note 1)	Creditor	Borrower	General ledger account	Is a related party	Maximum outstanding balance during the year ended	Balance at	Actual amount drawn down	Interest rate	Nature of loan	Amount of transactions with the borrower	Reason for short-term financing	Allowance for doubtful accounts	Collateral		Limit on loans granted to a single party (Note 2)	Ceiling on total loans granted (Note 3)	Footnote
					December 31, 2023	December 31, 2023							Item	Value			
0	The Company	Chiu Ho Medical System Co., Ltd.	Other receivables	Y	\$ 400,000	\$ 250,000	\$ -	2%	Short-term financing	\$ -	Operation	\$ -	None	\$ -	\$ 645,841	\$ 2,583,365	
0	The Company	Chiu Ho Scientific Co., Ltd.	Other receivables	Y	100,000	50,000	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Shin-Ho Instruments Co., Ltd.	Other receivables	Y	450,000	450,000	100,000	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Tomorrow Medical System Co., Ltd.	Other receivables	Y	350,000	150,000	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Hsing-Yeh Biotechnology Co., Ltd.	Other receivables	Y	100,000	100,000	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Chiu Ho Biotech Co., Ltd.	Other receivables	Y	30,000	30,000	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Hsin Lin Biotech Co., Ltd.	Other receivables	Y	60,000	-	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Tong-Lin Instruments Co., Ltd.	Other receivables	Y	50,000	30,000	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Hua Lin Instruments Co., Ltd.	Other receivables	Y	50,000	50,000	-	2%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
0	The Company	Treasure of Health Co., Ltd.	Other receivables	Y	100,000	100,000	60,000	2%~2.5%	Short-term financing	-	Operation	-	None	-	645,841	2,583,365	
1	Chiu Ho Scientific Co., Ltd.	High-End Vision Eye Center	Other receivables	Y	1,000	-	-	2.5%	Business transaction	10,226	-	-	None	-	10,226	61,218	
2	Hsing-Yeh Biotechnology Co., Ltd.	Yeezen General Hospital	Other receivables	Y	70,000	-	-	2.5%	Business transaction	218,703	-	-	None	-	200,266	400,533	
3	Chiu Ho (CHINA) Medical Technology Co., Ltd.	CHC Guangzhou Medical Technology Co., Ltd.	Other receivables	Y	24,516	24,231	-	3.45%	Short-term financing	-	Operation	-	None	-	22,571	45,143	
						<u>\$ 1,234,231</u>	<u>\$ 160,000</u>										

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:

(1) The Company is '0'.

(2) The subsidiaries are numbered in order starting from ‘1’.

Note 2: (1) In accordance with the Company's lending policies and procedures, the credit limit for each type of borrower is set as follows:

- A. For borrowers with which the Company has a business relationship, the individual loan amount cannot exceed the total transaction amount with the Company in the most recent year.
- B. For borrowers with short-term financing needs, the individual loan amount cannot exceed 10% of the Company's net assets according to the most recent financial statements.

(2) In accordance with the lending policies and procedures of the Company's subsidiary, the credit limit for each type of borrower is set as follows:

- A. For borrowers with which the subsidiary has a business relationship, the individual loan amount cannot exceed the total transaction amount with the subsidiary in the most recent year.
- B. The total loan amount granted to a single party cannot exceed 20% of the subsidiary's net assets according to the most recent financial statements.

Note 3: (1) Limit on total loans granted by the Company: Total loan amount cannot exceed 40% of the Company's net assets according to the most recent financial statements.

(2) Limit on total loans granted by the Company's subsidiary: Total loan amount cannot exceed 40% of the subsidiary's net assets according to the most recent financial statements.

CHC Healthcare Group and Subsidiaries
Provision of endorsements and guarantees to others
For the year ended December 31, 2023

Table 2

Expressed in thousands of NTD
(Except as otherwise indicated)

No. (Note 1)	Endorser/ guarantor	Party being endorsed/guaranteed Company name	Relationship with the endorser/ guarantor (Note 2)	Limit on endorsements/ guarantees provided for a single party (Note 3)	Maximum outstanding endorsement/ guarantee amount as of December 31, 2023	Outstanding endorsement/ guarantee amount at December 31, 2023	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company	Ceiling on total amount of endorsements/ guarantees provided (Note 4)	Provision of endorsements/ guarantees by parent company to subsidiary (Note 5)	Provision of endorsements/ guarantees by subsidiary to parent company (Note 5)	Provision of endorsements/ guarantees to the party in Mainland China (Note 5)	Footnote
0	The Company	Chiu Ho Medical System Co., Ltd.	2	\$ 12,916,829	\$ 1,532,000	\$ 1,250,000	\$ 156,910	\$ -	19.35%	\$ 19,375,244	Y	N	N	
0	The Company	Tomorrow Medical System Co., Ltd.	2	12,916,829	1,388,000	1,388,000	928,000	-	21.49%	19,375,244	Y	N	N	
0	The Company	Chiu Ho Scientific Co., Ltd.	2	12,916,829	150,000	150,000	49,159	-	2.32%	19,375,244	Y	N	N	
0	The Company	Hsing-Yeh Biotechnology Co., Ltd.	2	12,916,829	100,000	-	-	-	0.00%	19,375,244	Y	N	N	
0	The Company	Shin-Ho Instruments Co., Ltd.	2	12,916,829	771,000	771,000	673,480	-	11.94%	19,375,244	Y	N	N	
1	Chiu Ho Medical System Co., Ltd.	The Company	3	9,776,912	1,106,687	1,106,687	905,715	1,106,687	22.64%	14,665,369	N	Y	N	
1	Chiu Ho Medical System Co., Ltd.	Tomorrow Medical System Co., Ltd.	4	9,776,912	621,674	621,674	621,674	621,674	12.72%	14,665,369	N	N	N	
2	Chiu Ho (CHINA) Medical Technology Co., Ltd.	CHC (Guangzhou) Medical Technology Co., Ltd.	4	225,716	44,450	43,270	15,145	-	38.34%	338,574	N	N	Y	
						<u>\$ 5,330,631</u>	<u>\$ 3,350,083</u>	<u>\$ 1,728,361</u>						

Note 1: The numbers filled in for the endorsements/guarantees provided by the Company or subsidiaries are as follows:

- (1) The Company is '0'.
- (2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between the endorser/guarantor and the party being endorsed/guaranteed is classified into the following seven categories; fill in the number of category each case belongs to:

- (1) Having business relationship.
- (2) The endorser/guarantor parent company owns directly and indirectly more than 50% voting shares of the endorsed/guaranteed subsidiary.
- (3) The endorsed/guaranteed company owns directly and indirectly more than 50% voting shares of the endorser/guarantor parent company.
- (4) The endorser/guarantor parent company owns directly and indirectly more than 90% voting shares of the endorsed/guaranteed company.
- (5) Mutual guarantee of the trade made by the endorsed/guaranteed company or joint contractor as required under the construction contract.
- (6) Due to joint venture, all shareholders provide endorsements/guarantees to the endorsed/guaranteed company in proportion to its ownership.

(7) Joint guarantee of the performance guarantee for pre-sold home sales contract as required under the Consumer Protection Act.

Note 3: (1) In accordance with the Company's policies and procedures on endorsements and guarantees, the endorsement or guarantee amount for a single party cannot exceed 200% of the Company's net assets according to the most recent financial statements.

(2) In accordance with the policies and procedures on endorsements and guarantees provided by the Company's subsidiary, the endorsement or guarantee amount for a single party cannot exceed 200% of the subsidiary's net assets according to the most recent financial statements.

(3) In accordance with the Company's policies and procedures on endorsements and guarantees, the total endorsement or guarantee amount for a single party provided by the Company and its subsidiaries cannot exceed 200% of the Company's net assets according to the most recent financial statements.

Note 4: (1) In accordance with the Company's policies and procedures on endorsements and guarantees, the total endorsement and guarantee amount provided to external parties cannot exceed 300% of the Company's net assets according to the most recent financial statements.

(2) In accordance with policies and procedures on endorsements and guarantees provided by Company's subsidiary, the total endorsement and guarantee amount provided to external parties cannot exceed 300% of the subsidiary's net assets according to the most recent financial statements.

(3) In accordance with the Company's policies and procedures on endorsements and guarantees, the total endorsement and guarantee amount provided to external parties by the Company and its subsidiaries cannot exceed 300% of the net assets of the Company according to the most recent financial statements.

Note 5: Fill in 'Y' for those cases of provision of endorsements/guarantees by listed parent company to subsidiary and provision by subsidiary to listed parent company, and provision to the party in Mainland China.

CHC Healthcare Group and Subsidiaries
Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)
December 31, 2023

Table 3

Expressed in thousands of NTD
(Except as otherwise indicated)

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	As of December 31, 2023				Footnote
				Number of shares	Book value	Ownership (%)	Fair value	
The Company	Common stocks - Apex International Co., Ltd. - KY	-	Financial asset at fair value through profit or loss - current	200,000	\$ 10,080	0.11%	\$ 10,080	
The Company	Common stocks - Taiwan Semiconductor Manufacturing Company Limited	-	Financial asset at fair value through profit or loss - current	100,000	59,300	0.00%	59,300	
The Company	JAFCO Taiwan II Holdings Corp.	-	Financial assets at fair value through profit or loss - non-current	-	5,231	-	5,231	
The Company	Common stocks - S&S Healthcare Holding Ltd.	The Company's chairman and the investee's chairman are the same person	Financial assets at fair value through other comprehensive income - non-current	397,620	10,159	1.65%	10,159	
Chiu Ho Medical System Co., Ltd.	Preference stocks - Centaur	-	Financial asset at fair value through profit or loss - non-current	55,089	59,960	2.20%	59,960	
Chiu Ho Medical System Co., Ltd.	Common stocks - Huede Healthtech Co., Ltd.	-	Financial assets at fair value through other comprehensive income - non-current	200,000	-	3.33%	-	
Chiu Ho Medical System Co., Ltd.	Common stocks - AESolution Biomedical Co., Ltd.	The Company's chairman and the investee's chairman are the same person	Financial assets at fair value through other comprehensive income - non-current	855,400	26,800	6.69%	26,800	

CHC Healthcare Group and Subsidiaries
Acquisition of real estate reaching NT\$300 million or 20% of paid-in capital or more
For the year ended December 31, 2023

Table 4

Expressed in thousands of NTD
(Except as otherwise indicated)

Real estate acquired by	Real estate acquired	Date of the event	Transaction amount	Status of payment	Counterparty	Relationship with the counterparty	If the counterparty is a related party, information as to the last transaction of the real estate is disclosed below:				Basis or reference used in setting the price	Reason for acquisition of real estate and status of the real estate	Other commitments
							Original owner who sold the real estate to the counterparty	Relationship between the original owner and the acquirer	Date of the original transaction	Amount			
Shin-Ho Instruments Co., Ltd.	Plant construction of Tongluo irradiation business factory	2023/01/19	589,410	Payment based on the contract terms and progress	Xu Yuan Construction Co., Ltd.	-	-	-	-	\$ -	Not applicable because of engaging others to build on rented land	For operation	-

Note: The Company's Board of Directors approved a total budget of NTD\$950,000,000 for facility building and equipment purchasing on March 19, 2021. Shin-Ho Instruments Co., Ltd received user license and reclassified to property, plant and equipment-Building and structures on January 19, 2023.

CHC Healthcare Group and Subsidiaries

Purchases or sales of goods from or to related parties reaching NT\$100 million or 20% of paid-in capital or more

For the year ended December 31, 2023

Table 5

Expressed in thousands of NTD

(Except as otherwise indicated)

Purchaser/seller	Counterparty	Relationship with the counterparty	Transaction				Differences in transaction terms compared to third party transactions		Notes/accounts receivable (payable)		Footnote
			Purchases (sales)	Amount	Percentage of total purchases (sales)	Credit term	Unit price	Credit term	Balance	Percentage of total notes/accounts receivable (payable)	
Hsing-Yeh Biotechnology Co., Ltd.	Yeezen General Hospital	Substantive related party	Sale of goods	\$ 218,703	97%	6 months	-	-	\$ 189,736	92%	Note

Note 1: Sales amount includes rental revenue.

Note 2: Notes and accounts receivable include lease payments receivable.

CHC Healthcare Group and Subsidiaries
Receivables from related parties reaching NT\$100 million or 20% of paid-in capital or more
December 31, 2023

Table 6

Expressed in thousands of NTD
(Except as otherwise indicated)

Creditor	Counterparty	Relationship with the counterparty	Balance as at December 31, 2023	Turnover rate (Note 1)	Overdue receivables		Amount collected subsequent to the balance sheet date (Note 2)	Allowance for doubtful accounts
					Amount	Action taken		
Hsing-Yeh Biotechnology Co., Ltd.	Yeezen General Hospital	Substantive related party	Notes and accounts receivable (including lease payments receivable): \$189,736	1.17	\$ 71,325	In collection	\$ 31,608	\$ -
CHC Healthcare Group	Shin-Ho Instruments Co., Ltd.	Subsidiary	Other receivables: \$100,000	0.00	-	-	-	-

Note 1: Turnover rate shown as 0.00 is because the amount is shown as other receivables in parent company only financial statement and is not applicable to turnover rate. Please refer to table 1 for the amount regarding loaning to others.

Note 2: The subsequent collections were amounts collected as of March 13, 2024.

CHC Healthcare Group and Subsidiaries
Information on investees
For the year ended December 31, 2023

Table 7

Expressed in thousands of NTD
(Except as otherwise indicated)

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2023			Net profit (loss) of the investee for the year ended December 31, 2023	Investment income (loss) recognised by the Company for the year ended December 31, 2023		Footnote
				Balance as at December 31, 2023	Balance as at December 31, 2022	Number of shares	Ownership (%)	Book value				
The Company	Chiu Ho Medical System Co., Ltd.	Taiwan	Medical instrument sale, leasing and services	\$ 2,956,388	\$ 2,956,388	421,000,000	100.00%	\$ 4,844,794	\$ 300,318	\$ 300,012		Subsidiary
The Company	Tomorrow Medical System Co., Ltd.	Taiwan	Medical instrument sale, leasing and services	613,484	613,484	90,800,000	100.00%	1,002,938	17,290	17,290		Subsidiary
The Company	Chiu Ho Scientific Co., Ltd.	Taiwan	Ophthalmic equipment sale, leasing and services	151,422	151,422	9,853,841	100.00%	153,046	16,571	16,571		Subsidiary
The Company	Chiu Ho Biotech Co., Ltd.	Taiwan	Medical instrument leasing	226,822	197,182	23,963,988	100.00%	270,128	17,949	17,949		Subsidiary
The Company	Shin-Ho Instruments Co., Ltd.	Taiwan	Medical instrument leasing and irradiation business	219,171	219,171	21,300,000	100.00%	128,019 (	67,576) (	67,576)		Subsidiary
The Company	Tong-Lin Instruments Co., Ltd.	Taiwan	Medical instrument leasing	321,183	321,183	35,000,000	100.00%	443,195	38,488	38,532		Subsidiary
The Company	Hua Lin Instruments Co., Ltd.	Taiwan	Medical instrument leasing	321,815	381,815	35,600,000	100.00%	461,622	33,339	32,882		Subsidiary
The Company	Hsin Lin Biotech Co., Ltd.	Taiwan	Medical instrument leasing	-	25,929	-	-	-	1,462	1,131		Subsidiary (Note 1)
The Company	E Century Healthcare Corporation	Taiwan	Medical instrument leasing	396,151	476,151	44,000,000	100.00%	673,308	81,742	81,742		Subsidiary
The Company	CHC Healthcare (UK) Limited	United Kingdom	Medical instrument sale	7,364	7,364	200,000	100.00%	3,697 (	3,008) (	3,008)		Subsidiary
The Company	CHC Healthcare (BVI) Limited	British Virgin Islands	Holdings and indirect investments	522,432	522,432	940	100.00%	362,342 (	19,795) (	19,795)		Subsidiary (Note 2)

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2023			Net profit (loss) of the investee for the year ended December 31, 2023	Investment income (loss) recognised by the Company for the year ended December 31, 2023		Footnote
				Balance as at December 31, 2023	Balance as at December 31, 2022	Number of shares	Ownership (%)	Book value				
The Company	Treasure of Health Co., Ltd.	Taiwan	Drug and health supplements sale	\$ 335,070	\$ 335,070	5,814,000	51.00%	\$ 375,698	\$ 32,329	\$ 7,870		Subsidiary
CHC Healthcare (BVI) Limited	CHC Healthcare (HK) Limited	Hong Kong	Medical instrument sale, leasing and services	3,986	3,986	100,000	100.00%	41,064	466	466		Subsidiary
Chiu Ho Medical System Co., Ltd.	SenCare Healthcare Company	Taiwan	Consulting service, elderly residence and senior fitness	194,000	194,000	19,400,000	65.99%	188,551 (	1,475) (	973)		Subsidiary
Chiu Ho Medical System Co., Ltd.	PT CHC Medika Indonesia	Indonesia	Medical instrument leasing	5,358	5,358	2,566	100.00% (	938) (	1,031) (	1,031)		Subsidiary (Note 2)
Chiu Ho Medical System Co., Ltd.	Hsing-Yeh Biotechnology Co., Ltd.	Taiwan	Medical instrument sale and leasing ; drug sale	1,513,464	1,513,464	93,600,000	100.00%	1,606,698	31,179	26,636		Subsidiary
Hsing-Yeh Biotechnology Co., Ltd.	CHENG-HSIN Biotechnology Co., Ltd.	Taiwan	Management consulting services and retail sales of food products and drugs	12,000	12,000	1,200,000	40.00%	9,911	4,028	1,604		Associate
SenCare Healthcare Company	CHC Long-term Care Corporation	Taiwan	Long-term care services	31,040	31,040	-	97.00%	27,563 (	162) (	157)		Subsidiary (Note 3)
SenCare Healthcare Company	Cin-An Co., Ltd.	Taiwan	Elderly residence	54,361	-	1,667,789	51.00%	54,437	244	76		Subsidiary
SenCare Healthcare Company	Xing-An Long-term Care Corporation	Taiwan	Long-term care services	8,659	-	-	50.70%	9,111	923	452		Subsidiary (Note 3)
Tredsure of Health Co., Ltd.	Exotic Pet Care Experts Co., Ltd.	Taiwan	Veterinary medical instrument leasing and drug sale	4,080	-	408,000	51.00%	3,738 (	685) (	342)		Subsidiary

Note 1: The Group conducted a reorganisation where Hsin Lin merged with Chiu Ho Biotech on December 31, 2023. Chiu Ho Biotech was the surviving company.

Note 2: Indirect investment company is organised as a limited liability company.

Note 3: Investee is organised as an association.

CHC Healthcare Group and Subsidiaries
Information on investments in Mainland China
For the year ended December 31, 2023

Table 8

Expressed in thousands of NTD
(Except as otherwise indicated)

Investee in Mainland China	Main business activities	Paid-in capital	Investment method (Note 1)	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2023	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the year ended December 31, 2023		Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2023	Net income of investee for the year ended December 31, 2023	Ownership held by the Company (direct or indirect)	Investment income (loss) recognised by the Company for the year ended December 31, 2023 (Note 2)	Book value of investments in Mainland China as of December 31, 2023	Accumulated amount of investment income remitted back to Taiwan as of December 31, 2023	Footnote
				Remitted to Mainland China	Remitted back to Taiwan								
CHC (Guangzhou) Medical Technology Co., Ltd.	Medical instrument sale, leasing and services	\$ 291,830	(2) Indirect investment through CHC(BVI), a wholly- owned subsidiary of the Company	\$ 291,830	\$ -	\$ -	\$ 291,830	(\$ 9,960)	100%	(\$ 9,951)	\$ 199,578	\$ -	
Chiu Ho (CHINA) Medical Technology Co., Ltd.	Medical instrument sale, leasing and services	231,689	(2) Indirect investment through CHC(BVI), a wholly- owned subsidiary of the Company	231,689	-	-	231,689	(10,323)	100%	(10,323)	112,858	-	
Company name		Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2023		Investment amount approved by the Investment Commission of the Ministry of Economic affairs (MOEA)		Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA (Note 3)							
The Company		\$	523,519	\$	523,519	\$	4,065,303						

Note 1: Investment methods are classified into the following three categories; fill in the number of category each case belongs to:

- (1) Directly invest in a company in Mainland China.
- (2) Through investing in an existing company in the third area, which then invested in the investee in Mainland China.
- (3) Others

Note 2: Income (loss) recognised based on financial statements audited by independent auditors

Note 3: Disclosed in accordance with the investment limits set forth in Jin-Shen-Zi No. 09704604680, issued by the Investment Commission of MOEA on August 29, 2008

Note 4: The Company invested in the investees in Mainland China, including Neusoft CHC Medical Service Co., Ltd. through an existing company in Mainland China. Due to the existing company in Mainland China is a holding company, therefore it shall first submit an application for approval from Investment Commission of the Ministry of Economic Affairs (MOEA) for its reinvestments, but the approval from MOEA are not required for other investments.

CHC Healthcare Group and Subsidiaries

Major shareholders information

December 31, 2023

Table 9

Name of major shareholders	Shares	
	Number of shares held	Ownership (%)
Princeton Healthcare Limited	28,257,983	16.97%
Tien-Ying Lee	9,413,985	5.65%